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Trichomoniasis  also  known as  t rich , is  caused  by  pathogen ic 
p rotozoan  Trichomonas vag inalis (T.vag inalis), which  is the most 
common non-v iral sexually  t rans mitted  in fect ion (STI). 
Trichomoniasis  accounts  for more than  half o f all the curab le 
sexually  t rans mit ted in fect ions worldwide.[1]  It causes approximately 
180 million  in fect ions worldwide annually . Many  in fected  persons 
remain  asymptomat ic, when  symptomat ic, it p resents  with vag in it is, 
cerv icit is, PID and  in fert ility  in  women and  non-Gonococcal ureth rit is 
in  men . Women in fected  during  p regnancy  are p red isposed to  adverse 
p regnancy  outcomes  like p remature rup ture o f membrane, p remature 
labour and  low b irth  weight  in fants.[2]  
In fect ion  with  Trichomonas  vag inalis  is a  marker fo r h igh-risk 
sexual behav iour and  h igh  p revalence rates in  many  popu lat ions ind icate 
the need  fo r counselling  and  behav ioural change to  reduce pat ien ts ris ks 
fo r acqu iring  other STI and  Human Immunodeficiency  v irus 
in fect ion.[3][4]  Trichomonias is increases the risk o f t rans miss ion  o f HIV 
in fect ion  to  2 fo ld  rise due to  local in flammat ion  and  d isrupt ion  of 
cerv ical ep ithelial barrier.  
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Coinfect ion  with  T. vag inalis  and  HIV resu lts  in  “ep idemio log ical 
synergy” with  pro longed  o r augmented  in fect iousness  of both  the 
in fect ions.[3] [5]  
Trichomoniasis is  h igh ly p revalent  in sexually act ive women 
rang ing  from 5% to  74% and  in  men  p revalence is 5 % to  29%.  About 
10 to  50% of pat ients  harbor Trichomonads  without  develop ing  any 
symptoms  that serves  as major reservo ir o f in fect ion.[6]  
In  th is  background  we p lanned  to  conduct  a  study  to  d iagnose and 
compare Trichomonas in fect ion  in  asymptomat ic and  symptomat ic 
female pat ien ts  attend ing  STD outpat ient  department , us ing  wet  mount 













HISTORY   
Trichomonas vag inalis  was  first  described  in  1836 by  a French 
phys ician  A lfred  Donne who  observed  the o rgan is m in  fresh  p reparat ion 
o f vag inal d ischarge.[7]  It was designated  as Trichomonas vag inalis by 
Ehrenberg  in  1838.[8]The p rotozoa was  regarded  as  harmless inhab itant 
o f vag ina fo r longer period  and  in  1916 Hohne et  al ident ified  its ro le as 
causat ive agent  o f vag in it is .[7]  
In  1940, Koch’s  postulates  were fu lfilled  estab lish ing , T.vag inalis 
as  an  et io log ic agent  o f vag in it is.[9] [10]T.vag inalis  began  to  receive 
increased attent ion  as a cause of u rogen ital morb id ity  in  women and  in 
men  as  well.  In  1961, Lang  and  Ludmir d iscussed the ‘strawberry 
cerv ix’ appearance of ectocerv ix due to  the local ext ravasat ion  o f b lood 
resu lt ing  in  petech iae. Trussell et  al in  1942 first  reported  th is  in fect ion 
by  the flagellate in  a newborn . [8]  In  the d iagnos is  o f Trichomonas 
vag inalis infect ion , microscopy  and  the cu ltu re methods are most  widely 
used . In  1988 Kreiger et al developed  the an t ibody-based immuno-
h istochemical p rocedures.[11] 
EPIDEMIOLOGY  
Prevalence reports  fo r Trichomonias is  vary  widely  accord ing  to 
the d iagnost ic  method  used. Worldwide, the annual incidence of 
Trichomonas vag inalis  is estimated  to  be around  180 million  cases when 
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compared  with  89 million  cases o f Chlamydia, 62 million  cases of 
Gonorrhea and  12 million cases o f Syph ilis .[12]  
 Prevalence o f Trichomoniasis  varies from 2 to  60.6% in  d ifferent 
parts  o f Ind ia.[13][14]In  h igh-risk popu lat ion  and  STD clin ic attendee’s 
p revalence ranges  from 7 % to 74% in women and  5 to  29% in men .[15]  
A h igher p revalence of Trichomonias is was found  in  Blacks, 
mult iparous women, women married  at  early  age and  during 
p regnancy.[14]  Other ris k facto rs are mult ip le sexual contacts, poor 
personal hyg iene and  low socioeconomic status.[16]Trichomonias is 
associated  with  HIV in fect ion  can  facilitate its t rans mission  and 
acqu isit ion o f the v irus by  elicit ing  in flammatory response in  the vag inal 
ep ithelium. There is 2 to 3 fo ld  increase in  HIV t rans miss ion in 
Trichomonas vag inalis in fected  pat ients [17][18]  and  the p revalence rate of 
T. vag inalis  in  HIV pat ien t’s  ranges  from 9 to  30%.[19][20]  The possib le 
mechan is ms  fo r increased  t rans mission  o f HIV in  T.vag inalis  in fect ion 
are:[12]  
1) In fect ion  with  Trichomonas vag inalis resu lts in  an  in flammatory 
response, which  leads  to  recru itment  o f CD4 lymphocytes and 
macrophages to  the vag inal and cerv ical mucosa.  
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2) Trichomonas vag inalis has  a d irect cytopath ic effect  in  v it ro, 
resu lt ing  in  punctate microhaemorrhages  potent ially 
compromis ing  the mechan ical barrier to  HIV acqu isit ion.  
3) Trichomonas vag inalis  has been  shown to  be associated  with 
increased  v iral load  in  the seminal and  cerv ico-vag inal 
compartments.  
4) Finally , stud ies have shown that  Trichomonas vag inalis increases 
suscept ib ility  to  Bacterial vag inos is o r co lon izat ion  with  other 
abnormal vag inal flo ra that  in  turn  cou ld  increase ris k o f HIV 
acqu isit ion.  
Concomitant in fect ion  with  other sexually  trans mitted  in fect ions 
occurs  with  Trichomonias is.[21] Mixed  infect ions  with  Trichomonias is 
and  Neisseria Gonorrhoea and   Ch lamydia t rachomat is occurred  in  1.4% 
of 504 East  African  t ransport  workers while 61.5% of 91 men  with 
Trichomoniasis  in West  Africa had  co in fect ion  with Gonococcal 
in fect ion.[21]  
TRANSMISSION  
Sexual  trans mission  
Trichomonas vag inalis  is almost exclusively acqu ired  th rough the 
sexual contact with  in fected partner. The t rans miss ion rate is  as h igh  as 
14 to  60% in  men  after s ing le exposure to  an  in fected  woman [11] where 
as  Trichomonias is is  iso lated  from 67 to  100% in  female partner of 
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in fected men .[22] [23] Asymptomat ic men and women are the important 
reservo irs o f in fect ion. Trichomonias is detected  in  p repubertal age 
shou ld raise the susp icion  o f sexual abuse.[24]  
Non- venereal  trans mission 
Nonsexual t rans miss ion  can  occur by  contaminated  douche 
nozzles, specu lum, o r the to ilet  seats, th rough  which  Trichomonads  may 
find  their way into the vag ina.[25] However, such cases are  very  rare, 
because o rgan is m is  very  sens it ive to  des iccat ion . The live T.vag inalis 
has  been   found  in  u rine and  in  semen  after several hours o f exposure to 
air and  can  surv ive up  to  1hr in  to ilet seat, wet  clothes   and  swimming 
poo l water.[26]Prenatal trans mission  occurs  in  2 to 17% of female 
ch ild ren  of infected  mothers  and  may  be accompanied  by  suppurat ive 
nasal d ischarge and  resp irato ry  d istress.[20] [27]  
PARASITE TAXONOMY AND MORPHOLOGY  
Trichomonads  are flagellated  eukaryot ic microbes  that  belong  to 
the p rotozoan o rder Trichomonadida.Over more than 100 species are 
known and the most are commensals of intest inal t ract o f mammals and 
b irds. The th ree species found  in  humans  are Trichomonas vag inalis  of 
gen itourinary  t ract , Trichomonas  tenax o f o ral cav ity  and  Trichomonas 
Pentat richomonas homin is  o f intest ine.[27]Trichomonas represents one of 
the most  ancient  eukaryot ic lineages  considered  as  the p rimit ive 
eukaryote as it  lacks many featu res like mitochondria, peroxisomes and 
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28s ribosomes. [27] The size and  shape o f Trichomanads vary  depend ing 
on  the vag inal microenv ironment and  cu ltu ral cond it ions.Typ ically 
Trichomonads are pyriform shaped , 7-32 micrometer long, 5-
12micrometer wide and  rough ly the size o f leukocyte.  
Trichomonads assume amoeboid  fo rm once they  get  at tached  to 
the host  ep ithelium.[28]  They  are demonstrated  by  their classical errat ic 
twitch ing  mot ility  as they  are p ropelled  by  4 anterio r flagella  that 
o rig inates  from the kinetosomal complex. The 5th  flagella  o rig inates 
from the kinetosomal complex and  extends  halfway  down the o rgan is m 
attached  to  the undu lat ing  membrane supported  by  the complex array  of 
filaments  known as  costa. It  contains an  anterio r nucleus contain ing  five 
chromosomes, a  parabasal apparatus , a go lg i complex and  an  axosty le 
that  runs  cent rally  th rough  the cell and  p rot rudes from a posterio r tail or 
p ro ject ion. Parallel to  axosty le and  costa there are th ree rows  of large 
chromat ic g ranu les  includ ing  hydrogensomes. Hydrogenosomes  are 
characterist ic  o rganelles found  in  Trichomonas  vag inalis and  other 
p rotozoa that  lack mitochondria. These are doub le membrane bound 
st ructu res that generate hydrogen  and  ATP from the metabo lis m of 
pyruvate. 
Trichomonads are generally  thought  to  exist  on ly  in  the mot ile, 
vegetat ive t rophozo ite fo rm and  t rue cysts fo rm have not  been described. 
Under unfavourab le env ironmental cond it ions T.vag inalis  appear in 
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vit ro  as  pseudocysts.[30,31]  These Pseudocysts have altered  st ructu ral 
featu res like internalized  flagellae and  a compact  fo rm which  lacks a 
t rue cell wall.[32]  
 
Figure 1.S tructure of Trichomonas  vaginal is. 
T.VAGINALIS GENETICS AND BIOLOGY 
Trichomonads reproduce asexually  by  mitos is  fo llowed  by  the 
long itud inal cell d iv is ion . In  an  unusual p rocess known as closed 
mitos is, the paras ite  nuclear envelope remains intact  and  the mitot ic 
sp ind le is external to the nucleus. The results  of elect rophoret ic and 
cyto log ic analyses suggest  that  the T.vag inalis  nucleus  contains  six 
hap lo id  chromosomes.[33-35]The genomic sequencing  o f the p rotozoan 
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suggest  a  h igh ly  repet it ive genome of approximately  180 mega bases 
that  is  much  largerthan  ant icipated  bases on  earlier stud ies [36]  but  the 
exact  genome s ize and  chromosome number are uncertain . The hap lo id 
natu re o f T. vag inalis  is  confirmed  by  the ab ility  to  d isrupt  genes by 
homologous recombinat ion. [37 ,38] 
GROWTH AND METABOLISM 
The g rowth  and  mult ip licat ion  o f T.vag inalis  is opt imal in 
microaeroph ilic   o r anaerob ic cond it ions  with  the temperatu re range 
between 35°C and  37°C and  pH levels between  4.9 and  7.5.[27]The 
o rgan is ms  can  be cu lt ivated  in  nut rient  media with  the opt imum redox 
potent ial, pH, and  added  ant imicrob ials to  suppress other 
microorgan is ms .[39]  More robust, s maller o rgan is ms  are observed  at  pH 
5.5–5.8, whereas less mot ile  and  larger o rgan is ms  are encountered  at  pH 
levels lower o r h igher than  the opt imum pH .  
T.vag inalis  is an  aeroto lerant  anaerob ic p rotzoan  and  its  g rowth  is 
inh ib ited  at  h igh  oxygen  tensions  due to  deficiency  o f catalase.[40]This 
aeroto lerance is att ributed  to  the p resence o f act ive superoxide 
d is mutase and  whether oxygen  is absent  o r p resent, Trichomonal 
metabo lis m is  fermentat ive. 
Pyruvate p roduced  by  g lyco lys is in the cytoso l is  reduced to 
lactate in  the hydrogenosomes .T.vag inalis  hydrogenosomes  can  also 
metabo lize malate v ia decaboxylat ion  to  pyruvate. These o rganelles 
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contain  pyruvate-oxid izing enzymes (pyruvate-ferredoxin 
oxidoreductase) and  hydrogenase that  are linked  by  an  elect ron  t ransport 
p rotein  o f low redox potent ial.The Trichomonad hydrogenosomes are 
also importan t in  d rug act ivat ion . Metron idazo le and other 
n it ro imidazo les, used  in  the t reatment  o f Trichomoniasis , enter the cell 
by  passive d iffusion  in  an inact ive fo rm which  are subsequently 
act ivated  by  hydrogenosomes  to  act ive fo rm.[41] Electrons  requ ired  for 
d rug  act ivat ion  are thought  to  be p rov ided  by  2Fe-2S ferredoxin. 
(Ferredoxin-linked  elect rons are generated  during  oxidat ive 
decarboxy lat ion  o f pyruvate catalyzed  by  pyruvate: ferredoxin 
oxidoreductase). 
The mechan is m of development  o f anaerob ic res istance to 
Metron idazo le is cont ro lled  by  hydrogenosome in  that  Metron idazo le 
competes fo r hydrogen  ions  as  an  elect ron  accepto r. In  Metron idazo le-
res istant  Trichomonas vag inalis  the levels  o f hydrogenosomal enzymes 
(pyruvate-ferredoxin  oxidoreductase, ferridoxin , malic enzyme and 
hydrogenase) expression  is  reduced  d ramat ically , which  is likely to 
eliminate the ab ility  o f the paras ite  to  act ivate Metron idazo le.[29] 
Trichomonads, like most  other parasit ic  p rotozoa, are unab le to 
synthes ize purine ring  structures o r to  interconvert  purine nucleo t ides 
but  however it can  salvage the purine bases, aden ine and  guan ine and 
their nucleosides.[28]T.vag inalis  also possess hemolyt ic act iv ity  and  its 
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specific  associat ion  with  eryth rocytes (hemagglut inat ion) and 
subsequent  hemolys is are thought  to  be important  fo r destruct ion  of 
eryth rocytes in  menst rual b lood , with  the release of iron , lip ids  and  fatty 
acids fo r parasite  membrane b iosynthes is.  
PATHOGENESIS  
T.vag inalis penet rates  the mucous  layer and  gain  access to the 
underly ing  ep ithelial cells  and  attaches, resu lt ing  in  t issue damage and 
in flammat ion  with  the help  o f enzymes and  adhesins .[42]  
T.vaginalis enzymes and adhesins 
T .vag inalis  p roduces  many  p roteo lyt ic  enzymes  that  are invo lved 
in  cytotoxicity, hemolysis , evas ion  o f immune responses and  adherence. 
Trichomonal enzymes  are also  found  in  vag inal secret ions o f the 
in fected  women along  with  the ant ibod ies  that  recogn ize these 
enzymes .[42-44]  Trichomonads  b inds  to  mucin  in  v it ro , and  several 
secreted  p roteinases  can  degrade mucin  which  are act ive at   pH range of  
4.5–7.0[44] that is    cons istent  with  its ro le in  the vag inal, u reth ral, or 
p rostat ic  PH to  facilitate paras ite  penet rat ion o f the mucous barrier.  
A fter t ravers ing  the mucous  layer, Trichomonads  adhere to 
ep ithelial cells  that  mediated  by  paras ite  su rface adhesion  pro teins 
known as  APs. The o rgan is m contains  solub le and  membrane-associated 
enzymes  with phospho lipase A  (PLA) act iv ity . [45-47]These PLAs lyses 
the nucleated  mammalian cells and red  b lood  cells  in v it ro and 
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contribute to  t issue damage and  in flammat ion  in  Trichomoniasis . The 
d is rupt ion o f po larized ep ithelial monolayers by  T.vag inalis facilitate 
penetrat ion  o f HIV to  underly ing  layers. Trichomonads adhere no t on ly 
to  host  ep ithelial cells  but  also  to  the  ext racellu lar matrix components 
like fib ronect in  and  lamin in .[48]  Th is  b ind ing  o f t richomonads to  the host 
ext racellu lar matrix is  important  fo r the pers istence o f  in fect ion after 
the vag inal ep ithelium has  been  exfo liated , either by  paras ite-induced 
cytopatho log ical effects (CPE) o r shedd ing during  the menst rual cycle.  
Hos t component ass ociated with T .vag inal is 
Numerous host  macromolecu les  like alfa1-ant it rypsin , alfa 
2macrog lobu lin , fib ronect in , lactoferrin  and many  iron-b ind ing  and  iron-
contain ing  p roteins , lipoproteins [49]  are known to  coat  the Trichomonas 
vag inalis  cell su rface. These macro  molecu les  are important  fo r the 
surv ival o f the paras ite  in v ivo  and  cont ribute to Trichomonas vag inalis 
metabo lis m and pathogen icity either by  b io log ical mimicking  o r by 
accumulat ion  of nut rients from the host . The b ind ing o f host lactoferrin 
to  paras ite  su rface recepto r results  in  increased  iron  uptake by  the 
paras ite  which in  tu rn  resu lts in  increased  paras ite  int racellu lar enzyme 
act iv ity  and  the g rowth  o f paras ite  in  h igh  iron  poo l results  in  increased 




HOST IMMUNE RESPONSE 
In fect ion  with  T.vag inalis  elicits cellu lar, humoral and secretory 
immune responses. However, th is  response does  not  have p rotect ion 
against  rein fect ion . Repeated  in fect ions  are commonly  encountered  in 
women and  a h isto ry  o f p rior treatment  fo r Trichomonias is  itself is a 
ris k facto r   for in fect ion .[51]  
i ) Inflammatory res ponses 
The vag inal o r ureth ral in flammat ion  is  characterized  by  an  influx 
o f po lymorphonuclear leucocytes and it  represents the most obv ious  host 
response to infect ion  with  T.vag inalis. T.vag inalis  can  st imulate 
neut roph ils  to p roduce IL-8 th rough act ivat ion  o f to ll-like recepto r 4 
(TLR4).[52]  IL-8 is  a  potent  chemoatt ractant  p roduced  by  neu troph ils  and 
ep ithelial cells  in  response to  microb ial in fect ion, and  its st imulat ion 
likely  induces  fu rther neut roph il recru itment  to  the s ite  o f in fect ion. 
Increased  p ro in flammatory cytokine p roduct ion  in  Trichomoniasis  is 
cons istent  with  increased  HIV t rans miss ion , p rov id ing  an  exp lanat ion 
fo r the observed  ep idemio log ical synergy . T.vag inalis  also act ivates 
HIV-in fected  leucocytes  result ing in  TNF-alpha p roduct ion and 
increased v iral rep licat ion . [27]  
ii ) Antibody and complement 
The ant ibod ies  and  complement  components p resent  in  the serum 
and  gen ital flu ids  of the ind iv iduals with  Trichomonias is can b ind  the 
surface of T.vag inalis and  st imulate the neut roph il respiratory  burst 
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facilitat ing  paras it ic  killing  v ia classical and  alternat ive complement 
pathways. There is  litt le  ev idence that ant ibod ies  against  Trichomonal 
ant igens like heat  shock p roteins, cysteine p roteases  cont ribute to 
paras ite  clearance. Furthermore, pers istent Trichomonal infect ions , a 
hallmark o f Trichomonias is, suggest  that  humoral response is  not 
b road ly  pro tect ive.[53]T.vag inalis  resistance to  humoral immune 
response may  be due to  parasite  p roduct ion  o f p roteinases  that  can 
cleave human immunoglobu lins and complements . Expression  o f these 
p roteo lyt ic  enzymes  is  upregu lated  under certain  cond it ions  like h igh 
iron  levels  p resent  during  menstruat ion.However, there is  ev idence that 
ant ibod ies  that  b lock attachment  o f the parasite  to  mucosal surfaces 
cou ld  be p rotect ive.[54]  
CLINICAL PRESENTA TION 
Sites of Infection: 
In  women, T.vag inalis  has been  iso lated  from all gen itourinary 
s ites. Vag inal in fect ion  is  the most  common s ite  fo llowed  by  in fect ion 
o f the u rethra, Bartho lin ’s g lands, Skene’s g lands and  endocerv ix.[27] 
While concomitant infect ion  o f the u rethra occurs in  a majority  of 
women with  vag inal Trichomonias is. Among  women infected  with 
T.vag inalis, almost  10% demonstrated  pos it ive cu ltures on ly  from the 




i ) Infection in women 
The spect rum of clin ical p resentat ions  with  T.vag inalis  in fect ion 
ranges  from asymptomat ic d isease, to  severe vag in it is. The incubat ion 
period  fo r T.vag inalis  in fect ion  has been  reported  to  be between  4-28 
days .[28]  About  50% of women are asymptomat ic, but about 30% of th is 
g roup  develop  symptoms  when  they  are observed  fo r 6 months.[56]  The 
most  common present ing  complaint  among  women d iagnosed with 
T.vag inalis  is  vag inal d ischarge, seen   in  more than  50% of cases, 
fo llowed  by  p ruritus  o r dysuria and  abdominal pain. One study  o f 200 
Nigerian  women demonstrated  74% with  vag inal d ischarge were 
in fected  with  T.vag inalis .[2]  The vag inal d ischarge can  have any  co lour 
and  be malodorous. The other symptoms include p ruritus, dysuria and 
abdominal pain. Some women remain  asymptomat ic unt il after menses, 
suggest ing a ro le fo r iron in the pathophysio logy o f Trichomoniasis .[50]  
On gen ital examinat ion , vu lvar ery thema and  edema may  be 
noted .  On  specu lum examinat ion , the vag inal d ischarge can  have any 
co lo r o r characterist ic  frothy yellow or g reen ish d ischarge. The vag inal 
walls  may  also  appear ery thematous. Co lp it is  macu laris  o r ‘strawberry 
cerv ix’ is  a  result  o f microscop ic, punctate hemorrhages  on  the cerv ix, 
th is may  be observed in  lesser than 5% of women with  Trichomonias is. 
However, a large p roport ion  o f Trichomonias is cases with co lp it is 
macu laris  can  be ident ified  us ing  co lposcopy.[27]Although  uncommon, 
th is  find ing  is  h igh ly  specific  fo r Trichomonias is. The result ing 
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cerv icit is  may  lead  to  postco ital b leed ing  and  cerv ical friab ility. 
Cerv ical mucopuru lence and/o r cerv ical erythema have also  been 
observed , but  these find ings  are neither sensit ive nor specific;  other 
STIs  such  as  Gonorrhoea and  Chlamydial in fect ion  shou ld  also  be 
cons idered .  
Women with  Trichomonias is  are more likely  to  p resent  with  an 
elevated  vag inal pH, amine odor, milky  d ischarge, o r co lon izat ion  by 
Gardenella vag inalis , Bacteriodes  species  o r gen ital Mycoplasamas  than 
women with  normal vag inal flora. Since the vag inal env ironment  for 
Trichomoniasis  and  Bacterial vag inosis  (BV) are same, BV is  found 
concomitant ly  in 25-60% of women with Trichomonias is.[27]  
ii ) Recurrent and persistent Trichomoniasis 
The common source o f recurrent  Trichomonias is is  an  unt reated 
partner and  organ is ms that are res istant to  ant imicrob ial therapy.[53]No 
clin ical symptoms  or s igns can  d ifferent iate between suscept ib le or 
res istant  in fect ions . A  h isto ry  of potent ial reexposure o r sexual act iv ity 
with  an  unt reated  sexual partner shou ld  allow d ifferent iat ion  between 
rein fect ion  and  persistent  in fect ion . 
Factors associated with Trichomonas vag inalis  infection in women 
Because o f non-specific  clin ical p resentat ion, stud ies  have 
focused  on ident ify ing  p red icto rs o f in fect ion  in women. Facto rs 
associated  with  Trichomonas vag inalis in fect ion  are g iven  in  tab le 1. 
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Reproductive complications  in women 
Trichomonas  vag inalis  is  associated  with  a variety  o f adverse 
health  consequences  in  both  men  and  women. The associated 
morb id it ies and complicat ions  in  women include: 
 Ris k facto r fo r HIV trans mission . [66]  
 Associated  with  pelv ic in flammatory  d isease. [67] 
 Greater ris k fo r tubal in fert ility. [11] 
 Ectop ic p regnancy. [28]  
 Premature rupture of membranes, preterm birth and low birth weight. [11] 
 Increased  ris k o f post-hysterectomy in fect ion . [2]  
 Ris k facto r fo r cerv ical neop lasia.  [62]  
 Neonatal pneumonia in  bab ies born  to  mothers  with  T.vag inalis 
in fect ion.[20]  
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Table-1: Factors independently associated with T.vaginalis infection. 
Demograph ic 
characterist ics  
U.S African  American  race.[57]  
Low educat ion  attainment.  [58]  
Unemployment . 
Behav ioral 
characterist ics  
Sex with  non-steady partner.  [59]  
Separated  women. 
Prostitu t ion.  [59]  
Failu re to  use cont racept ion . [60]  
Self-reported  in fert ility .  [61]  
Smoking .  [62]  
A lcoho l.  [63]  
In ject ing d rug  abuse.  [64]  
Marijuana use.  [65]  
Clin ical 
characterist ics  
Older women (30-49 years ).  [64]  
Vag inal pH >5. 
Concomitant  sexually  t rans mitted  in fect ions-
Chlamydia, Gonorrhoea, Bacterial vag inos is, 
Mycoplas ma homin is, Ureap las ma. [65]  
DIAGNOSIS 
Diagnos is o f Trichomoniasis  based  on  the class ical clin ical 
symptoms  o f yellowish-green  frothy  d ischarge, p ru ritus , dysuria, 
dyspareun ia, and “strawberry” cerv ix[68]cannot  be made so lely  because 
o f fo llowing reasons: 

 The clin ical symptoms  o f Trichomonias is is  synonymous 
with  those of other STDs .[69-72] 

 The class ic find ing  “strawberry” cerv ix is  approximately 
seen  in  2% of pat ients .  
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
 The frothy  d ischarge is  seen  in  on ly  12% of women with 
Trichomonas vag inalis .[24]  
 In  1980, Fouts  and  Kraus demonst rated  that  if on ly  the classic 
featu res are used  alone in  the d iagnosis  o f Trichomoniasis , as  many  as 
88% of in fected women will not  be d iagnosed  and  29% of un in fected 
women will be falsely d iagnosed as hav ing  in fect ion.[24]Hence the 
clin ical manifestat ions  are not reliab le d iagnostic parameters and  the 
laboratory  invest igat ions  are necessary  fo r the accurate d iagnos is  of 
Trichomoniasis .  
METHODS OF SPECIMEN COLLECTION  
VAGINAL:[73 ]  
 Clean  the external gen italia  us ing  a sterile  gauze s wab  moistened 
with  sterile  normal saline 
 Insert a warmed  vag inal specu lum moistened  with  sterile  saline. 
 Material is  obtained  under d irect  v is ion  from the posterio r and 
lateral forn ices  of the vag ina us ing sterile cotton  ⁄ dacron  swabs  or 
d isposab le 10µL bacterio log ical loops . 
 In  women who  have undergone hysterectomy, specimens  are taken 
from lateral forn ices o f the vag ina. 
 Vaginal s wabs from unmarried  women are perfo rmed through  the 
hymen  open ing  from the posterio r wall o f vag ina (a specu lum 
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shou ld  not  be used) o r specimens  can  be ob tained  from the 
int ro itus . 
FIRST CATCH URINE: [73 ]  
The FCU specimen  (approximately  10–15 mL) has  to  be co llected 
into  a sterile  container. The u rine may be cent rifuged  and  the pellet 
tested . However, the sens it iv ity  o f u rine test ing  is  lower than  that  of 
vag inal sampling . 
DIRECT MICROSCOPIC EXAMINATION 
Diagnos is  o f Trichomonas  vag inalis  infect ion  in  most  parts  o f the 
world  is  carried  out  by  saline wet  preparat ion  method. T.vag inalis  is 
ident ified  as  pear-shaped  organ is ms  about  the size o f a  pus cell with 
typ ical jerky  /errat ic twitch ing  movement. In  most  o f the cases, 
increased numbers o f po lymorphonuclear leucocytes are p resent . The 
Trichomonas vag inalis  is d ifficu lt to  d ifferent iate from the nucleus  o f a 
vag inal ep ithelial cell when  it  is  immot ile.  Mot ility  is dependent  main ly 
on  the temperatu re o f the specimen . At room temperatu re in phosphate-
buffered  saline, the organ is m will remain  alive fo r more than  6 h rs 
however, the mot ility  o f the o rgan is m becomes s ign ificant ly  at tenuated 
at  lower temperatu res.[73]Diagnosis  by  wet  mount  requ ires  v isualizat ion 
o f v iab le, mot ile  p rotozoa and  hence specimens must  be examined 
immediately . The wet  mount  techn ique has low s ensit iv ity  o f 30 to 
80%.[74]  The sens it iv ity  o f wet -mount  is fu rther reduced as a resu lt  of 
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even  short  delays  between  specimen  co llect ion  and  microscop ic 
examinat ion .[75]  
The accuracy o f the d iagnos is is  dependent  on two  factors :  
 The specimen  shou ld remain  moist to  retain  v iab ility and 
therefo re the mot ility  o f the Trichomonads (the microscopy 
shou ld  be perfo rmed  with in  30 min  o f p reparat ion  of the wet 
mount) and  
 The microscop ist  should  be skilled  in  recogn izing 
Trichomonads.[76]  
A  min imum of 104 o rgan is ms  per milliliter of vag inal flu id 
appears to  be necessary  for the ident ificat ion  of the Trichomonas 
vag inalis  by  wet  mount. The various  stain ing  methods  like acrid ine 
o range, Giems a, fluorescein , neut ral red , immunoperoxidase and 
Period ic Acid-Sch iff have been  described  to  improve the sens it iv ity  of 
microscop ic evaluat ions. Rout ine Papan ico loau stained s mears have 
demonstrated  T.vag inalis  on  cyto log ical examinat ion  in  asymptomat ic 
women.[77]However, detect ion  us ing  the Papan ico laou  test results  in  a 
h igh  percentage o f false-negat ive resu lts with  a sens it iv ity  o f 60% and  a 
specificity o f 95–97%.[77,78]  Confirmat ion  o f the find ing  of 
Trichomonads us ing another method  is  recommended . 
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Accord ing  to  the 2006 gu idelines  fo r the t reatment  o f STI 
pub lished  by  Centre fo r Disease Contro l and  Prevent ion  (CDC), a 
cu ltu re o f vag inal secret ions  is  recommended  when  T.vag inalis is 
suspected  clin ically  but  not  seen on  a wet mount .[79]  
CULTURE 
Cultu re in  liqu id  medium has  remained  the go ld  standard  fo r the 
d iagnos is  o f Trichomonas  vag inalis  in fect ion  fo r the past  40 years  and 
has  the h igher s ensit iv ity  o f 71-100% and  specificity  of 100%.[27]  It  is 
very  usefu l method  when  the o rgan is m load  is  low as in  asymptomat ic 
women and  men  with  chron ic d isease, as  it  requ ires  as  few as  300-500 
Trichomonads/ml o f inocu lum to  in it iate g rowth  in  cu ltu re.[28]  The 
various  media that  have been  used  to  detect  Trichomonads  are Diamond 
(Tript icase, yeast and maltose), Modified  Diamond, Kupferberg’s 
Trichosel medium, Lash, NIH, Feinberg-Whitt ington  media and  cysteine 
peptone liver media (CPLM). The fo rmulat ions  o f Diamond  medium are 
superio r to  that  of Kupferberg  o r Lash  medium for the g rowth  of 
Trichomonas vag inalis .[80]  
 The standard  b roth  used  is  Diamond’s  medium, eventually 
modified  accord ing to Fouts  and  Kraus, i.e . with  strep tomycin rep laced 
by  net ilmicin.[73] The  Incubat ion period  of 2–7 days is  requ ired  to  iso late 
Trichomonas vag inalis in  cu ltu re.[81]Even  when b roth  cu ltu res are spiked 
with  ant ib iot ics  to  reduce contaminat ion  by  vag inal flora, contaminat ion 
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with  bacteria is  the major p rob lem. Passage o f the cu ltu res  after 2–3 
days  to  reduce the bacterial contaminat ion  may  be requ ired  to  iden t ify 
Trichomonas  vag inalis  defin it ively . The o rgan is m has  the capacity  to 
enter lag  g rowth  and  even  in  well-estab lished  axen ic cu ltu re and  can 
somet imes have at tenuated  g rowth  for 24–48 h  before re-estab lishing  its 
characterist ic  log/day  growth .[73]  Due to  the expense of the techn ique, 
cu ltu re has  not  been  read ily  availab le in  many  cent res , but  would  be the 
most  effect ive way  o f estab lishing  the t rue ep idemio logy  of 
Trichomoniasis  vag inalis , part icu larly  where STI clin ics are remote from 
the clin ical laborato ry.  
To  circumvent these p rob lems , systems such as the InPouch TV 
cu ltu re system have been  developed  whereby  the specimen  is  inocu lated 
into  a two-chambered  bag , allowing  sampling fo r immediate wet  mount 
microscopy and incubat ion  for cu lture. Trichomonas vag inalis  is an 
anaerob ic o rgan is m that  g rows  more s lowly  under aerob ic cond it ions. It 
is  importan t to  note that  Trichomonas vag inalis shou ld  be g rown at  the 
bottom of the pouch  and  the pouches ough t  to  be incubated  in  a vert ical 
pos it ion . The use o f InPouch  TV cu ltu re system has been  shown to  be at 
least as  effect ive as Diamond’s medium.[73, 82]  
Cu ltu re o f T.vag inalis shou ld  be perfo rmed  using  either liqu id  or 
semi liqu id  cu ltu re media in  tubes. The vo lume of the media should  be 
not  less than  5ml.[73]  
 33 
IMMUNOLOGICAL TESTS  
Sero log ical d iagnos is by  Agglu t inat ion , Ind irect 
hemagglut inat ion , Complement  fixat ion, Gel d iffusion , Fluorescent 
ant ibody , and  Enzyme-linked  immunosorbent  assay are used to 
demonstrate the presence of ant itrichomonal ant ibod ies . Since the 
Trichomonal ant ibod ies can persist  fo r a  longer t ime after t reatment, 
cu rrent  and  past  in fect ions  cannot  be d istingu ished  by  these tests. 
Monoclonal ant ibod ies to  immunogens 62k-Da and  65-kDa proteins  for 
the detect ion  o f T.vag inalis  from the clin ical specimens  have shown 
s imilar resu lts  as wet-mount  p reparat ions .[73]  
Rap id  d iagnost ic  test  like latex agg lut inat ion  test  have made the 
p rompt d iagnosis  of in fect ion  possib le and  same day  t reatment .[73]  
MOLECULAR METHODS 
Nucleic acid  amplificat ion tests like Po lymerase Chain React ion 
(PCR) have improved  the sensit iv ity  of d iagnosis  of 
T.vag inalis.[83]Unlike PCR for STI like Gonorrhoea and  Chlamydia for 
which  amplificat ion  results have g reater sensit iv ity  than  cu ltu re 
methods, the current ly  pub lished amplificat ion  techn iques for 
Trichomoniasis  in  women do  not  appear to  offer a  s imilar d iagnost ic 
advantage. However, PCR is  superio r to  cu ltu re fo r d iagnos is  of 




Defin it ive therapy  fo r Trichomonias is  is  by  n it ro imidazo les 
(metron idazo le, t in idazo le, o rn idazo le, carn idazo le, and  n imorazo le).  
Top ical metron idazo le is  not effect ive fo r the therapy  of 
Trichomoniasis .[84]  The Centers fo r Disease Contro l and  Prevent ion 
(CDC) has  est imated  that  5% of clin ical iso lates o f T vag inalis  exh ib ited 
some degree o f Metron idazo le resistance.[85] Metron idazo le res istance 
may  p red ict  Tin idazo le res istance. The CDC has p roposed  an  escalated 
therapeut ic reg imen  fo r the management  of infect ion  with  resistant 
st rains. Other d rugs like  fu razo lidone, a  n it ro fu ran , was shown to  be 
effect ive in  v it ro  against  both  laborato ry  and  clin ical specimens  with 
h igh  level metron idazo le res istance. 
RECOMMEND ED REGIMEN: [86] 
1 . CDC reg imen (2010) 
 Tab Metron idazo le 2g o rally in  s ing le dose   (o r) 
 Tab Tin idazo le 2g  orally  in s ing le dose.  
A lternat ive reg imen  
 Tab Metron idazo le 500mg orally  twice daily  fo r 7 days. 
In pregnancy 
 Tab Metron idazo le 2gm orally  in  sing le dose. 
In neonatal infections  [87]  
 Tab Metron idazo le 5 mg/kg  o rally  th ree t imes daily  for 5 days. 
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Treatment Failures  [88-90]  
Recommended  reg imen  
 Tab Metron idazo le 500mg twice daily  fo r 7 days. (o r) 
 Tab Metron idazo le 2g o rally once daily  fo r 3-5 days. 
A lternat ive reg imen  
 Tab Tin idazo le 2 g twice daily  fo r 14 days .      (o r)                
 Tab Tin idazo le 500 mg th ree t imes  daily  for 7–10 days .   (or) 
 Tab Tin idazo le 1.5 g  th ree t imes  daily  fo r 14 days .  (o r) 
 Tab Tin idazo le 1 g twice daily  fo r 14 days  .  
Note 
 Pat ien ts on  Metron idazo le and  other imidazo les  should  be 
caut ioned  not  to  consume alcoho l while they  are taking  the d rug, 
and  up  to  24 hours  after taking  the last  dose. 
 Metron idazo le is  not  recommended  in  the first  trimester of 
Pregnancy . 
 Asymptomat ic women with  Trichomonias is shou ld  be treated  with 




2 . WHO regimen (2003) 
 Tab Metron idazo le 2g o rally s ing le dose.(or) 
 Tab Tin idazo le 2g  orally  sing le dose.(o r) 
 Tab  Metron idazo le 400 mg orally twice daily  fo r 7days.(o r) 
 Tab. Tin idazo le 500 mg twice daily fo r 5days. 
3 . NACO regimen(2007)  
 Tab. Metron idazle 2g  o rally  s ing le dose. (o r) 
 Tab.Tin idazo le 2g  orally  sing le dose. (or) 
 Tab. Metron idazo le 400mg orally  twice daily fo r 7days. 
4 . Syndromic management 
Vaginal Discharge syndrome: Green  Kit : Tab.Secn idazo le 2gm 
s ing le dose stat  and  Tab . Fluconazo le 150mg sing le dose stat . 
Partner treatment 
Partners  o f pat ients  with  Trichomoniasis   who  have had  sexual 
contact  with  the index pat ient  in  the past  60 days  shou ld  be not ified  for 
evalut ion  and  the ep idose shou ld  be g iven  and  sexual abst inence is 





Fol low up 
The pat ients are rev iewed after seven  days o f treatment  if 
symptoms  persist . The rein fect ion  shou ld  be carefu lly  excluded. Pat ients 
not  cu red  fo llowing  in it ial therapy  often  respond favourab ly  to  repeat 
t reatment with  the seven-day reg imen .The resistance to the 5-
n it ro imidazo les may  be an  another cause fo r treatment  failu re. 
Pat ien ts not  cured  with  the repeated  course o f metron idazo le can 
be t reated  with  tab let metron idazo le 2 g  o rally  daily , together with 500 
mg app lied  int ravag inally  each n igh t fo r 3–7 days. In travag inal 
metron idazo le  are on ly recommended  fo r the t reatment  o f  refractory 
in fect ions along  with  o ral medicat ion  and  not  fo r the p rimary  therapy  of 
Trichomoniasis . A lternat ively  Metron idazo le 400mg or 500mg orally 
twice daily  fo r seven  days can  be used. 
PREVENTION AND CONTROL 
 Partner not ificat ion and treatment . 
 The p romot ion  o f condom use and  other barrier methods. 
 Vaccinat ion  and  immunity  
Abraham et al [91] were ab le to  induce immunity to T.vag inalis in  
mouse model, which  lead  to  the development  o f vaccine.Immunity  to 
in fect ion is  d ifficu lt to induce in humans because even repeated 
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in fect ions do  not  confer immune p rotect ion  desp ite demonst rab le 
ant ibod ies in  serum and  vag inal secret ions.  
To  date on ly  one vaccine had  been  produced  against  T vag inalis. 
The So lco  Trichovac vaccine which  was  p repared  from inact ive 
lactobacilli and  was  thought  to  work by  inducing  ant ibod ies to  abnormal 
lactobacilli and  T.vag inalis  without  adversely  affect ing  the g rowth  of 
normal lactobacilli in  the vag ina.[91]  However, lack o f ant igen ic 
s imilarity  between  th is  vaccine and T.vag inalis  was shown,[92] wh ich 
makes  th is   cross-react ion  hypothes is  un likely  and  the clin ical trials  of 















AIMS AND OBJECTIVES 
1) To study  the p revalence o f symptomat ic and  asymptomat ic  
Trichomonas in fect ion in  female pat ients attend ing  STD OP. 
2) To study  sensit iv ity pattern  of wet mount  and  cu ltu re. 
3) To study  d isease characterist ics and  associated  STD in fect ions 
with  Trichomoniasis. 




MATERIALS AND METHODS 
STUDY DESIGN 
Cross-sect ional study . 
STUDY GROUP 
 500 female pat ients were enro lled in the study . 250 symptomat ic 
and  250 asymptomat ic pat ients  are selected  randomly . Pat ients  with 
complaints  o f vag inal d ischarge, dysuria, dyspareun ia, p ru ritus, lower 
abdominal pain  are taken  as  symptomat ic g roup , and  pat ients  attend ing 
STD OP fo r rout ine checkup  & fo r screen ing  are taken  as  asymptomat ic 
g roup . 
 4 vag inal swabs were taken  from the posterio r fo rn ix o f each 
pat ient , one s wab  was  used  for wet  mount  p reparat ion  and  another s wab 
was  inocu lated  d irect ly  into  the DiamondsTYIS-33 medium and  other 
two  swabs  were used fo r KOH and  Grams  stain ing  respect ively . 
The Inst itute eth ics commit tee clearance was obtained and 
in fo rmed consent was taken  from the recru ited  women.  
INCLUSION CRITERIA 
 Pat ien t aged  > 18yrs and < 55yrs. 
 Female pat ient  attend ing STD OP with complaints o f vag inal 
d ischarge, dysuria, dyspareun ia, pru ritus , LAP are taken  as 
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symptomat ic g roup , and  pat ients  attend ing  STD OP fo r rout ine 
checkup  & fo r screen ing are taken  as  asymptomat ic g roup. 
EXCLUSION CRITERIA  
 Pat ien ts aged  <18 to  > 55yrs. 
 Pregnant , lactat ing  and  menstruat ing women.   
 Pat ien ts taken  t reatment  with  any  ant ib iot ics  includ ing 
Metron idazo le  3 weeks p rio r to  study period . 
 4 Pat ients  with  severe medical d isorder. 
HISTORY 
A detailed  h isto ry  was  obtained  pertain ing  to  the fo llowing 
parameters  - age, occupat ion , socioeconomic status, educat ional status, 
marital h istory , sexual, cont racept ive, obstet ric , past, personal, recent 
t reatment h isto ry , h istory  suggest ive of systemic ailments, and  sexually 
t rans mitted  in fect ions  related symptoms  as per the p ro forma enclosed. 
EXAMINATION 
A thorough  gen ital examinat ion  was done using  Cusco’s  self 
retain ing  b ivalve specu lum and  the abnormalit ies  in  the vu lva, vag ina 
and  cerv ix were noted .  The amount , odour, co lour and  cons istency  of 
vag inal d ischarge were noted . The d ischarge was  labelled  scanty  if it 
was  insufficient  to  co llect  on  the specu lum;  moderate if it  was su fficient 
to  co llect  on  the specu lum and  p rofuse if it  was  v isib le at  the int ro itus 
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even  before specu lum insert ion. The vag inal pH was  measured  d irect ly 
us ing  pH ind icato r st rips against the lateral vag inal wall or over 
specu lum b lade.  
SAMPLE COLLECTION 
A sterile  cot ton  swab  was  used  to  co llect  the vag inal d ischarge 
from the posterio r vag inal fo rn ix under d irect  v is ion  and  the specimen 
was  subjected  to  a series  o f laborato ry  tests. However, in  v irg in  females, 
the specimen  was  obtained  from the intro itus. A  b imanual examinat ion 
was done in all excep t v irg ins  to look fo r adnexal tenderness.  
LABORATORY INVESTIGATIONS 
From each  pat ient  examined , four samples  o f vag inal d ischarge 
from the posterio r fo rn ix were co llected with  sterile  co tton s wabs.  
1) The first s wab  was sub jected immediately to  wet  mount 
microscopy us ing normal saline to observe fo r mot ile 
Trichomonads under 100X and 400X magnificat ions.  
2) W ith  the second  sample, a  10% potassium hydroxide (KOH) 
mount  was  p repared  and  whiffed  fo r the p resence o f fishy  odour 
(Amine test ) and  the s ame was  examined  fo r the p resence of 
budd ing  yeast  cells  under 100X and 400X magnificat ions.  
3) The th ird  sample was  immediately  inocu lated  d irect ly  and  s wirled 
into  the Diamond medium (prepared at Department o f Sero logy, 
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Inst itute o f Venereo logy . MMC). The cu ltu re tubes with  5ml of 
the b roth  were incubated  in anaerob ic atmosphere at  350 C.  
4) The fourth  sample was  st reaked  on  to  a microscopic slide for 
Gram stain  fo r the p resence o f clue cells , yeast cells  and  pus  cells 
under 1000X magnificat ion .  
A ll part icipants  underwent  cu ltu re fo r Gonoccous , b lood  VDRL 
and  tested  fo r HIV ant ibod ies.  
DIAGNOSIS  
1.Trichomonias is : Diagnosis  was made based  on  the fo llowing : 
Wet mount:  
A  d rop  of normal saline was put  over a clean  , g rease free  
microscop ic slide. To th is  a  d rop o f vag inal flu id  was added  and mixed 
well. A  cover s lip  was  put  over the mixtu re, so  that  there was  a un ifo rm 
spread  without  air bubb le. The s lide was  observed  under 40 x 
magnificat ion o f the ob ject ive. 
Read ing : Pear shaped  flagellated  o rgan is ms  approximately  the 
s ize o f lymphocyte (10-20 µm) or that  o f a  s mall neut roph il with 
characterist ic  jerky  movements. 
Culture:  
Diagnos is  is  made by  perfo rming  wet  mounts  from the drop  of 
Diamond’s cu ltu re media fo r ev idence o f mot ile  Trichomonads by 
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examin ing  cu ltu res  after 48 hours o f incubat ion  and on  3rd, 5th  and 7th 
day . 
2. Bacterial  vaginosis: Diagnos is  was made based  on  Amsel’s 
criteria  in  which  p resence o f th ree out  o f the four criteria  is 
necessary :  
a . Excessive homogenous un ifo rmly  adherent  vag inal d ischarge. 
b . Vaginal pH more than  4.5. 
c . Posit ive amine test (Whiff test). 
d . Presence o f clue cells  on  microscop ic examinat ion . 
3. Candidiasis: Diagnos is was made based  on pos it ive microscopy 
and/o r cu ltu re.  
4. Mucopurulent cervici tis: Those pat ients  whose Gram’s  stain  of 
cerv ical s mear hav ing  30 o r more po lymorphonuclear leukocytes 
per o il immers ion  field  in  cerv ical mucus . 
5. Pelvic inflammatory disease (PID): A d iagnosis o f PID was 
made if in  add it ion  to  the p resent ing  symptoms  o f abnormal 
vag inal d ischarge and lower abdominal pain, adnexal tenderness 




Diamonds  TYIS  medium: 
Ingred ients : fo r 1000ml. 
1. Trypt icase -20gm. 
2. Yeast  ext ract -10gm. 
3. Maltose -5gm.  
4. L.Cysteine hydrogen phosphate- 0.5gm.  
5. L.Ascorb ic acid - 0.2gm. 
6. Dipotass ium  hydrogen  phosphate -0.8gm. 
7. Potassium d ihydrogen  phosphate -0.5gm. 
8. Agar -0.5gm. 
In  900ml o f d ist illed  water. 
PROCEDURE  
1) Mix the content  in d ist illed  water. 
2) Autoclave the medium at 1150c fo r 20min . 
3) Cool the medium to  500c and  add  100ml o f horse serum and 
10mg% ch loramphen ico l. 
4) Pour 5ml o f media into p re-sterilised  screw capped g lass tubes of 
15ml capacity . 
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5) Lable the tubes . 
6) Stored  at  40c t ill use. 
Culture method 
Cultu re is  the go ld  standard  for the d iagnos is o f T.vag inalis . The 
vag inal d ischarge specimen  is inocu lated  in the Diamond’s medium, for 
opt imal g rowth  the medium is filled  in long  g lass tube so as to p rov ide 
anaerob ic cond it ion  at  the bot tom. The inocu lum is  p laced  at  the bottom 
of  the tube and  incubated  at  370c, and  observed  fo r the g rowth  under 
microscope from 2nd  day  onwards  .Tubes  are incubated  t ill 7days  before 
declaring  it  negat ive. 
Observations : Turb id ity in the cu ltu re media suggests growth . A 
wet  mount  is  then  p repared  from a d rop  o f media flu id  and  observed 
under light  microscope fo r mot ile  T.vag inalis.  
STATISTICAL ANALYSIS 
The data co llected  was  tabu lated  in  Microsoft  Excel Worksheet 
and  computer-based  analysis  was perfo rmed  using  the SPSS 13.0 
software (SPSS, Chicago , IL, USA). The categorical variab les were 
summarized  as  p roport ions and  percentages . The cont inuous  variab les 
were summarized  as  mean  and  standard  dev iat ion . For comparison  of 
p roport ions, Ch i-square test  was used . In  cases where any  one o f cell 
value was less than five, Fisher's  exact test was  used.  
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OBSERVATIONS AND RESULTS 
The p resent study  was conducted  in  the Inst itu te of Venereo logy, 
Madras  Medical Co llege, Chennai, to assess the p revalence of 
Trichomoniasis  in  symptomat ic and  asymptomat ic female pat ients 
attend ing  STD OPD using  wet  mount and cu ltu re. The study g roup  was 
d iv ided  into  2 main  g roups: 
a) Symptomat ic group : Cons ist ing  of 250 pat ients. 
b ) Asymptomat ic g roup : Cons ist ing o f 250 pat ien ts. 
Pat ien ts who  p resented  with  complaints o f vag inal d ischarge, 
dysuria, dyspareun ia, p ruritus, lower abdominal pain  and  other 
gen itourinary symptoms were taken  as symptomat ic g roup, and  pat ients 
attend ing  STD OPD for rout ine checkup  & fo r screen ing  were taken  as 
asymptomat ic g roup. [History  cou ld no t be elicited in one o f the pos it ive 
pat ient  o f asymptomat ic g roup  who  was referred  from inst itute o f mental 
health  fo r screen ing .] 
The data co llected  is  analyzed  us ing  Chi square test  and  the stat ist ical 
s ign ificance was cons idered  if p  value is <0.05. 
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DEMOGRAPHIC PARAMETERS OF STUDY POPULATION 
1 . Age group 
The age d istribut ion   o f study   popu lat ion  are shown in  tab le 2. The 
mean  age group  o f pat ients  in  symptomat ic g roup  is  33.85±9.65 and  in 
asymptomat ic g roup the mean age is 34.25±9.36. 
Table-2 . Age dis tribution of study population. 
Age Group 
(In years ) 
S ymptomatic Group 
(N=250) 
As ymptomatic Group 
(N=250) 
≤25 48 [19.2%] 51 [20.4%] 
26-35 99  [39.6%] 92 [36.8%] 
>35 103 [41.19%] 107[42.8%] 
Total 250 [100%] 250[100%] 
Mean ±SD 33.85±9.65 34.25±9.36 
Range 18-55 18-56 
                    
Fig 2 : Age Distribution of S tudy Group. 
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2.  AREA OF RESIDENCE 
Most  of the pat ients  in  our study  g roup were from urban  areas, 
which  const ituted  72.2%, and about  27.8% are from rural areas . Figure 3 
shows  the area o f d istribut ion  of res idence in our study g roup . 
Table 3: Area of Resi dence of Study Group.  




Urban  185(74%) 176(70%) 361 (72.2%) 
Rural 65(26%) 74(30%) 139 (27.8%) 






Fig 3 :  Area of Residence of Study Group. 
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3. SOCIOECONOMIC STATUS 
Our study  g roup  was  strat ified  into  various socioeconomic classes 
as  per Kuppus wamy’s  socioeconomic status scale. The SE status o f our 
study  group  is  shown in  tab le 4. The majority  o f pat ients  in  symptomat ic 
g roup  121 (48.40%) belonged  to  upper lower class (Class-IV) and  about 
63 (25.20%) pat ien ts were in  lower class (Class-V), 56 (22.40%) 
pat ients were in  lower midd le class (Class-III). In  asymptomat ic g roup, 
148(59.19%) women belonged  to  lower class (Class-V). The figure 4 
and  5 shows  Socioeconomic status  o f symptomat ic and  asymptomat ic 
g roup  respect ively . 
Table 4 : Socioeconomic S tatus of the S tudy Group. 
S E s tatus S ymptomatic Group  (N=250) As ymptomaticGroup               (N=250) 
 Upper midd le 10 [4.0 %] 0 [9.2%] 
 Lower midd le 56 [22.40 %] 23[42.8%] 
 Upper lower 121 [48.40%] 78[31.2%] 




Fig 4 : S ocioeconomic Status of Symptomatic Group. 
 
Fig 5 : S ocioeconomic Status of Asymptomatic Group. 
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4. EDUCATION STATUS 
The educat ion  status o f the study  group  is  shown in  tab le 5. About 
128 (51.2%) women in  symptomat ic g roup and 143 (57.19%) women in 
asymptomat ic g roup had educat ional status  upto  6th to  12th standard . 
Table-5 .  Education status of the study Group. 
Education s tatus  S ymptomatic Group (N=250) 
As ymptomatic Group 
(N=250) 
Illiterate 22 [8.79] 41 [16.40] 
Primary  100 [40.0 %] 66 [26.40%] 
6th -12 th  128 [51.2 %] 143[57.19%] 
 
 
Fig 6 .  Education status of the S tudy Group. 
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5. MARITAL STATUS 
Majority  of women in  our study  group  are married  (92% in 
symptomat ic g roup  and  96.39% in  asymptomat ic g roup) and  liv ing  with 
their husbands. About  20% women in  symptomat ic g roup  and 
2.4%women in asymptomat ic g roup  were liv ing  sing le. 
Table-6: Marital  Status of the S tudy Group. 
Marital  status S ymptomatic Group  (N=250) As ymptomatic Group (N=250) 
Married   230 (92%) 242 (96.39) 
Sing le 20 (8%) 6 (2.4%) 
W idow  0 1(0.4%) 
 
 




 6. PRE/EXTRAMARITAL CONTACT 
A h isto ry  of p remarital o r ext ramarital contact  was p resent  in  27 
(10.80%) women in  symptomat ic g roup  and  30 (12%) women in 
asymptomat ic g roup.  




S ymptomatic Group 
(N=250) 
As ymptomatic Group 
(N=250) 
Present  27 [10.80 %] 30[12%] 
Absent   223 [89.2%] 220 [88%] 
 
 




7. PROMISCUITY OF THE PARTNER 
The Partners o f 13 women (5.2%) in symptomat ic g roup and two 
women (0.8%) in  asymptomat ic g roup  had  h isto ry  o f ext ramarital 
contact . The conserned  women however had no  extramarital contact . 
Table-8 . Promiscuity of the partner in Study Group. 






Absent  166 [66.40%] 228 [91.20%] 
Present  13 [5.2 %] 2[0.8%] 
Unknown 50 [20 %] 16[6.4%] 
Not  app licab le (For s ing le 












Absent Present Unknown Not applicable
Symptomatic Group Asymptomatic Group
 
Figure-9. S hows  Extramarital Contact of the Partners in Study 
Group. 
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STUDY PARAMETERS OF TRICHOMONAS POSITIVE 
PATIENT 
PREVALENCE OF TRICHOMONIASIS IN STUDY GROUP  
 In  our study a total of 8% of women had  Trichomonias is out  of 
500 women examined . 31 out  of the 250 women (12.4%) in  symptomat ic 
g roup  had  in fect ion  with  T.vag inalis   by  cu lture  and  /o r wet  mount  and 
9 ou t  o f 250 (3.6%) asymptomat ic women had   Trichomonias is    by 
cu ltu re and/o r wet mount . 
Table-9:  Prevalence of Trichomoniasis in Study Group 
No. of patients  S ymptomatic group 
As ymptomatic 
group 
Trichomonas pos it ive 
cases 
31 (12.4%) 9 (3.6%) 
Trichomonas negat ive 
cases 
219 (87.6%) 241(96.4) 





Fig 10: Prevalence of Trichomonas  posi tive patients in Study Group. 
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DEMOGRAPHIC AND SOCIOECONOMIC FACTORS  
1 . Age 
The tab le 10 shows  age d ist ribut ion  o f Trichomonas pos it ive 
pat ients  in  both  symptomat ic and  asymptomat ic g roups . The mean  age 
g roup  of Trichomonas pos it ive pat ients in  symptomat ic g roup is  32±7 
years  whereas  in asymptomat ic g roup  mean  age is 34±8 years. 
Table-10 . Shows Age Dis tribution in Trichomoniasis patients. 
S ymptomatic Group As ymptomatic Group Age Group 
(In years ) Trichomonas Posi tive Trichomonas Posi tive 
≤25 4  [12.9%] 1[11.1%] 
26-35 19[61.3%] 7[77.8%] 
>35 8  [25.8%] 1[11.1%] 
Total 31[100%] 9[100%] 
Mean ±SD 32±7 34±8 



















Symptomatic Group Asymptomatic Group
 
Figure11 . Age Dis tribution among Trichomonas  Posi tive Patient. 
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2 .  Area of residence 
Most  o f the pos it ive pat ients  were from urban  areas which 
const ituted 67% and the ru ral inhab itants  const ituted  about  33%. 
Table-11: Area of residence of Trichomonas Positive Patients  
S ymptomatic  
Group 
As ymptomatic 






Urban  21 (67.7%) 6 (67%) 27 (67%) 
Rural 10 (32.2%) 3 (33.3%) 13 (33.3) 
To tal 31 (100%) 9 (100%) 40 (100%) 
 
Fig12.  Area of residence of Trichomonas posi tive cases in study 
group. 
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3 . Socioeconomic s tatus : 
Our study  g roup  was  strat ified  into  various socioeconomic classes 
as per   Kuppus wamy’s   socioeconomic status scale shown in tab le 12. 
The majority  o f Trichomonas pos it ive pat ients 17(54.8%) in 
symptomat ic g roup  belonged  to  the lower socioeconomic class (class V). 
About  10 (27.3%) pat ients were in  upper lower class (class IV), 3 
(9.7%) pat ients  in lower midd le class (class III) and  one (3.2%) pat ient 
in  upper midd le class  (class  II).  In  asymptomat ic g roup  majority  of 
pos it ive pat ients 6 (75%) belonged  to  upper lower class (class IV) 
fo llowed  by  2 pat ien ts (25%) in  lower class (class  V).The p  value is 
0.001 when  compared  to  Trichomonas  negat ive pat ients, which  is 
stat ist ically s ign ificant .  
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Table-12 . Socioeconomic S tatus of Trichomoniasis Patients  in S tudy 
Group. 
Patients  
S ymptomatic Group As ymptomatic group 
Trichomonas Trichomonas 




S E s tatus 
N %  N %  
Upper midd le 1 3.2 0 0 
Lower midd le 3 9.7 0 .0 
Upper lower 10 32.3 6 75.0 
Lower  17 54.8 2 25.0 

















Upper Middle Lower Middle Upper Lower Lower 
Symptomatic Group Asymptomatic Group
 
Figure-13. S ocioeconomic S tatus of Trichomonas posi tive Patients . 
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4 . Education status 
The table 13, shows the Education status of Trichomonas positive 
patients in the study group.  Most of the women in symptomatic group had 
education level upto 6 -12th standard, whereas in asymptomatic group majority 
of patients with Trichomoniasis (87.5%) were in primary education status level. 
Table-13 . Education Status of Trichomonas  Posi tive Patients in 
S tudy Group. 
Patients  
S ymptomatic Group As ymptomatic Group 
Trichomonasis Trichomonasis 
Posi tive Posi tive 
Educational 
status  
N %  N %  
Illiterate 4 12.9 1 12.5 
Primary  12 38.7 7 87.5 
6th - 12th  14 45.2 0 .0 















Illiterate Primary 6th-12th Professional
Symptomatic Group Asymptomatic  Group
 
Figure 14. Education S tatus of Trichomonas posi tive Patients in 
S tudy Group. 
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5 . Marital s tatus  
Majority  o f women (74.2%) in  our study were married and  liv ing 
with  their husbands.  About  25% women were liv ing  sing le in  the 
Trichomonas pos it ive pat ients  o f symptomat ic g roup  and  25% women 
were s ing le and  12.5% women were widowed  in  asymptomat ic pos it ive 
g roup .The p  value is  <0.05 when  compared  to  Trichomonias is negat ive 
s ing le(5.5%) pat ients  in  the study. 
Table 14 . Marital s tatus  of Trichomoniasis patients  in s tudy group 
Patients  
S ymptomatic Group As ymptomatic Group 
Trichomoniasis Trichomoniasis 
Posi tive Posi tive 
Marital  status 
N %  N %  
Married  23 74.2% 5 62.5% 
Sing le 8 25.8% 2 25% 
W idow 0 .0% 1 12.5% 
Total 31 100.0 8 100.0 
 
Figure 15. Marital  Status of Trichomoniasis Patients in Study 
Group. 
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6 . Pre/Extramarital contact. 
The history of Premarital or Extramarital contact was present in 14 
(45.2%) of positive patients when compared to negative patients13(5.9%) in 
symptomatic group. About 10 Trichomoniasis positive women in our study 
group indulged in prostitution as compared to 4 women in Trichomoniasis 
negative group. The p value is 0.001 which is statistically significant. 
Table-15 . Pre/Extramarital contact in Trichomoniasis Patients of 
study group. 
Patients  
S ymptomatic Group As ymptomatic Group 
Trichomonasis Trichomonasis 
Posi tive Posi tive 
Pre/extramarital 
contact 
N % N % 
Present  14 45.2 4 50.0 
Absent  17 54.8 4 50.0 
To tal 31 100.0 8 100.0 
 
Figure-16. Pre/  Extramarital  contact in Trichomonas  posi tive 
patients. 
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7 . Promiscuity of the Partner.  
The husbands of seven (22.6%) women with Trichomoniasis in 
symptomatic g roup had extramarital contact. This was significantly h igher 
as compared to those without Trichomoniasis (2.7%) in the study group.  
The p  value is 0.001 which  is stat ist ically s ign ificant . 







Posi tive Posi tive 
 
 
Promiscuity of the partner 
N %  N %  
Present  7 22.6 0 .0 
Absent  9 29.0 3 37.5 
Unknown 8 25.8 3 37.5 
Not  app licab le (for s ing le 
women) 
7 22.6 2 25.0 
To tal 31 100.0 8 100.0 
 
Figure 17: Promiscuity of the Partner in the Trichomonas Patients. 
 65 
8 . Contraception 
Majority  o f the married  women in  our study  were Tubectomised 
in  bo th  the groups  i,e  14(45.2%)  and   9(100% )of posit ive cases in 
symptomat ic and  asymptomat ic women respect ively  . Only  7(22.6%) 
women in  posit ive cases used  barrier methods as cont racept ive.when 
compared  to   Trichomonas  negat ive pat ients(15.6%). The p  value is 
>0.05 (Nons ign ificant ). 
Table-17. Method of contraception in Trichomoniasis Positive Study Group. 
Patients  
S ymptomatic Group As ymptomatic Group 
Trichomonasis Trichomonasis 
Posi tive Posi tive 
Contraception 
N %  N %  
Sterilizat ion  14 45.2% 8 100.0% 
Barrier 7 22.6% 0 .0% 
IUCD 2 6.5% 0 .0% 
Not  Fo llowed  8 25.8% 0 .0% 



















Sterilization Barrier IUCD Not Followed
Symptomat ic Group Asymptomatic Group
 
Figure-18. Contraception method in Trichomonas  Posi tive Patients. 
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9 . Obs tretic history 
In  our study  12.9% of Trichomonas pos it ive women had  h isto ry  of 
abort ion  when  compared to  on ly  0.5% in  Trichomonas negat ive 
pat ients.The p value is <0.05 which  is stat ist ically s ign ificant . 
 Table-18 . Obs tretic His tory of S tudy Groups . 
Patients  
S ymptomatic Group As ymptomatic Group 
Trichomonasis Trichomonasis 
Posi tive Posi tive 
Obs tretic 
history 
N %  N %  
Normal 
delivery  
15 48.4% 4 50.0% 
LSCS 3 9.7% 4 50.0% 
Abort ion  4 12.9% 0 0% 
Nullipara 9 29.0% 0 0% 




















Normal delivery LSCS Abortion Nullipara
Symptomat ic Group Asymptomatic Group
 
Figure-19. Obs tretic History of Trichomonas Posi tive Patients . 
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10 . Symptoms  in Partner. 
In  our study  6.5% of partners  o f Trichomoniasis  pat ients  in 
symptomat ic g roup  had  u reth rit is , pru ritus  and  dysuria. In  partners  of 
Trichomonas negat ive women 5.5% had  u reth rit is, 1.5% had  balan it is 
and  none had dysuria. The p value is  <0.5 which  is  stat ist ically 
s ign ificant . 
Table-19 . Symptoms  in Partners  of the Study Groups . 
Patients  
S ymptomatic Group As ymptomatic Group 
Trichomoniasis Trichomoniasis 
Posi tive Posi tive 
S ymptoms in partner 
N %  N %  
Unknown 21 67.7% 5 62.5% 
Ureth rit is  2 6.5% 1 12.5% 
Dysuria 2 6.5% 0 0% 
Balan it is  3  9.7% 0 0% 
Pruritus 2 6.5% 0 0% 
Others  0 0% 1 12.5% 
No Symptoms  (Nil) 1 3.2% 1 12.5% 
Total 31 100.0 8 100.0 
 
Figure-20.  S ymptoms  in Partners of Trichomonas posi tive women. 
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 11 . S ubs tance Abuse. 
Only  two  Trichomonias is  pos it ive cases  in  asymptomat ic group 
had  h isto ry o f alcoho l abuse. 
Table-20 . Shows S ubs tance Abuse in S tudy Groups . 
Cas es 
S ymptomatic As ymptomatic 
Trichomonasis Trichomonasis 
Posi tive Posi tive 
Subs tance 
abuse 
N %  N %  
Yes  0 .0 2 25.0 
No  31 100.0 6 75.0 
To tal 31 100.0 8 100.0 
12 . Past history of PID/  Infertili ty/  Venereal  disease.                                      
About 6 (19.9%) women with Trichomoniasis in symptomat ic group 
had previous history suggestive of venereal d isease and 3 (9.67%) women 
had  history  suggestive of  PID. Where as 2 women with Trichomoniasis 
in asymptomat ic g roup had h istory of venereal disease (22.2%).  
Table-21 . Past History of PID/Infertili ty/Venereal  disease. 
S ymptomatic Group As ymptomatic Group Pas t his tory of 
 Trichomonas posi tive Trichomonas posi tive 
PID 3(9.67%) 0 
In fert ility  0 0 
Venereal d isease 6(19.35%) 2(22.2%) 
None 22(70.96) 6(77.7%) 
Total 31(100%) 9 
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B). DISEASE CHARACTERISTICS IN TRICHOMONAS 
POSITIVE PATIENT 
1 . Age of onset of Vaginal Discharge. 
The mean  age o f onset  o f d ischarge in  Trichomoniasis pat ients in 
both  symptomat ic and asymptomat ic g roup  is 34. 
Table 22 . Age of onset of Discharge is S tudy Group. 
Trichomonasis Age of Onset (years) S ymptomatic S ymptomatic Total 
Mean 30 - 30 
Standard  Deviat ion  7 - 7 
Median  30 - 30 
Min imum 16 - 16 
Posit ive 
Maximum 40 - 40 
Mean  34 - 34 
Standard  Deviat ion  10 - 10 
Median  33 - 33 
Min imum 15 - 15 
Negat ive 
Maximum 60 - 60 
 
 70 
2 .Duration of Vaginal  Discharge. 
Majority  o f women (77.4%) with  Trichomonias is  in  symptomat ic 
g roup  had  h istory  o f vag inal d ischarge fo r less than  one year. 
Table 23 . Shows  Duration of Vaginal  Discharge is Study Group. 
Patients  
S ymptomatic Group As ymptomatic Group 
Trichomoniasis Trichomoniasis 
Posi tive Posi tive 
Duration of 
vag inal  discharge 
N %  N %  
Less  than  one year 24 77.4 0 .0 
More than  one year 7 22.6 0 100.0 
To tal 31 100.0 9 100.0 
 
Figure-21. Duration of Vaginal  discharge in Trichomonas  posi tive 
patients in s ymptomatic group. 
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3 .  Relation to menstruation. 
In  our sttudy 64.5%women gave h isto ry  of increased  symptoms 
during  menstruat ion when compared to negat ive cases that  had  on ly  20% 
of similar h isto ry. The p value is <0.05 which is  stat ist ically s ign ificant. 





Group Total  
Trichomonasis Trichomonasis Trichomonasis 
Negative Posi tive Negative Posi tive Negative Posi tive 
Relation to 
mens truation 
N %  N %  N %  N %  N %  N %  
Yes  44 20.1 20 64.5 0 .0 0 .0 44 20.1 20 64.5 
No  175 79.9 11 35.5 0 .0 0 .0 175 79.9 11 35.5 
To tal 219 100.0 31 100.0 0 .0 0 .0 219 100.0 31 100.0
 
Figure-22. Relat ion  between  Mestruat ion  and  Vaginal d ischarge in  
Trichomonas Posit ive Pat ients. 
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4 . Other s ymptoms . 
Vaginal itch ing  (29%) and  lower abdominal pain  (9.7%) was  the 
most  common symptoms  seen  in  Trichomonas  pos it ive women fo llowed 
by  dysuria which is  seen  in 3.2% women. 







Posi tive Posi tive 
 Others s ymptoms  
N %  N %  
1 Vulval itch ing  9 29.0 0 .0 
2 Dysuria 0 .0 0 .0 
3 Lower abdominal pain  3 9.7 0 .0 
4 Dyspareun ia 0 .0 0 .0 
5 Post co ital b leed ing  0 .0 0 .0 
7 Ulcer 0 .0 0 .0 
8 Growth/swelling  1 3.2 0 .0 
1,2 Vulval itch ing, Dysuria 1 3.2 0 .0 
1,3 Vulval itch ing, LAP 7 22.6 0 .0 
1,5 Vulval itch ing , Post  co ital 
b leed ing  
0 .0 0 .0 
1,7 Vulval itch ing, Ulcer 0 .0 0 .0 








Posi tive Posi tive 
 Others s ymptoms  
N %  N %  
2,5 Dysuria, Post co ital b leed ing  0 .0 0 .0 
1,3,5 Vulval itch ing , Lower abdominal 
pain , Post co ital b leed ing , 
0 .0 0 .0 
6 None 8 25.8 9 100.0 
 Total  31  100 .0  9  100 .0  
 
 
Figure-23. Other symptoms seen  in  Trichomonas Posit ive women in  
Symptomat ic group . 
 
 74 
5 . Vulvovaginal  Examination 
About  12.9% women of Trichomonias is had  erythema of vu lva 
and  vag ina which  is s ign ificant  when  compared to on ly  2.7% of women 
in  negat ive pat ients. About  90.3%women in  Trichomonas  pos it ive cases 
in  symptomat ic g roup  and  100% of women in  asymptomat ic g roup  had  
vag inal d ischarge, which  is  not  s ign ificant  when  compared  to  89% in 
negat ive pat ients (p  >0.05). 











N %  N %  
Normal 27 87.09% 9 100.0 
Erythema 4 12.9% 0 .0 
Growth  0 .0 0 .0 
Vulvar examinat ion 
Ulcer 0 .0 0 .0 
Present  1 3.2 0 .0 Gen ital u lcers  
Absent  30 96.8 9 100.0 
Present  28 90.3 9 100.0 
Absent  3 9.7 0 .0 
Vag inal d ischarge 
To tal 31 100.0 9 100.0 
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6 . Vaginal  Discharge characteristics in Trichomonas  posi tive 
patients. 
Most  of the women (48.4%) with  Trichomonias is in  symptomat ic 
g roup  had  moderate to  p ro fuse whit ish  d ischarge (58.1%) and  64.5% 
women had fou l s melling  d ischarge. Where as  in  asymptomat ic 
Trichomoniasis  pat ients  the vag inal d ischarge was  moderate, odourless 
and  mucoid  in  natu re. The Typical frothy  d ischarge was seen  on ly  in 
58% of women in symptomat ic g roup  and  in  on ly  two (22.2%) pat ients 
o f asymptomat ic pat ients. Puru len t d ischarge was seen  in 38% and 33% 
of Trichomonas pos it ive women in symptomat ic and  asymptomat ic 
women respect ively .  
 Table 27 . Vaginal  Discharge characteristics in Trichomonas 







Posi tive Posi tive 
Vaginal  
dis charge  
N %  N %  
Scanty  3 9.7 2 22.2 




Profuse 13 41.9 2 22.2 
Odourless 9 29.0 6 66.7 












Posi tive Posi tive 
Vaginal  
dis charge  
N %  N %  
Curdy  0 .0 0 .0 
Floccu lent  1 3.2 1 11.1 
Th ick 
homogeneous  
1 3.2 0 .0 
Frothy  18 58.1 2 22.2 
Watery  5 16.1 2 22.2 
Discharge 
cons istency  
Mucoid  6 19.4 4 44.4 
White 18 58.1 6 66.7 
Grey ish  1 3.2 0 .0 
Puru lent  12 38.7 3 33.3 
Serosangu inous 0 .0 0 .0 
Discharge 
co lour 
To tal 31 100.0 9 100.0 
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C. Investigations and Diagnosis.  
1 . Wet mount 
The Wet  mount  Preparat ion  us ing  normal saline had  low 
sens it iv ity  and  h igh  specificity.Wet  mount  was  posit ive in  67.74% of 
symptomat ic group  and  55.5% of asymptomat ic g roup . Even  though  Wet 
mount  failed  to  ident ify  32.25% of in fect ion  in  symptomat ic g roup  and 
35% of asymptomat ic Trichomoniasis  pat ients  respect ively. (p  value is 
>0.05 (Not  s ign ificant ), ch isquaretest  = 0.455, Fisher exact test >0.05). 
 Table-28 . Sensi tivi ty pattern of Wet mount. 
Trichomonasis Patients 
S ymptomatic As ymptomatic Total  Wet mount 
N %  N %  N %  
Posit ive 21 80.8 5 19.2 26 100.0 
Negat ive 10 71.4 4 28.6 14 100.0 













Symptomatic Group Asymptomatic Group
Wet mount (Pos it ive) Wet mount (Negative)
 
Figure 24. Percentage of Wet mount Positivity in the Study. 
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2 . Culture: 
Cultu re done us ing  Diamond’s  liqu id  media had  sens it iv ity  and 
specificity  o f 100%, PPV (100%), NPV(100%) when  observed  with  in  3 
days  of inocu lat ion .Cultu re examined on  7thday  had  Sens it iv ity (77.50%), 
Specificity  (100%), PPV(100%) and  NPV(98.5%).  
Table-29 . Culture: Us ing  Diamond’s  medium 




Group Total  
 
N %  N %  N %  
Present 31 100% 9 23.1 40 100.0
Cultu re on  2nd  
and  3rd  day  
Absent  0 0 0 .0 0 0 
Present 30 96.77% 9 23.1 39 100.0
Cultu re on  5th  day  
Absent  1 3.22% 0 100.0 1 100.0
Present 24 77.41% 9 29.0 31 100.0
Absent  6 19.35% 0 .0 6 100.0
 Cultu re on  7th  
day  
To tal 31 77.5 9 22.5 40 100.0
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3 . Wet mount method compared with culture: 
Wet mount  method  had  low sens it iv ity  in  d iagnosing  both 
symptomat ic and  asymptomat ic pat ien ts when  compared  to  cu ltu re. (p 
value is < 0.05, Fischer exact  test <0.05, ch isquare test=161.95 in 
symptomat ic g roup  which  is  s ign ifican t  and  the p  value is  <0.05, Fisher 
exact  test <0.05, ch isquare test  =136.6 in  asymptomat ic g roup  and  is 
s ign ificant ) 
Table-30: Comparision of Wet mount and Culture in Diagnosis of 
Trichomonas vaginalis. 
Culture in s ymptomatic 
Group 
Culture in as ymptomatic 
Group Wetmount 
Posi tive Negative Posi tive Negative 
Wetmount  
Posit ive 
21 (67.74%) 0  5 (55.55%) 0 
Wetmount  
Negat ive 
10 (32.25%) 219 4 (44.44%) 241 
















Culture Posit ive in symptomatic Group 100% Culture Positive in asymptomatic Group 100%
Wetmount Posit ive Wetmount Negat ive
 
Figure-25. Percentage of Wet mount and Culture Positivi ty. 
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4 . Other Inves tigative Methods  Compared with Culture:  
Cu ltu re had  100% sens it iv ity  and  specificity , and  considered  as 
go ld  standard  procedure. However in  our study  the sens it iv ity  o f cu ltu re 
reduced  from 100% to  77.5% done on  3rd  and  7th  day  respect ively . (Low 
sens it iv ity  is p robab ly  due to  g rowth  inh ib it ion by  bacterial and/or 
cand idal contaminat ion o f the medium). 
Wet  mount  method had low sensit iv ity (65%) but h igh  specificity 
(100%), h igh PPV (100%), NPV (93.75%) and  LR (74.75). 
The pH > 4.5 had  sensit iv ity  o f 82.5% and  specificity  o f 79.1% in 
d iagnos ing  Trichomonias is.  
Whiff test had  sensit iv ity  of 60% (which  was comparab le  to  wet 
mount) and specificity  o f 82%. 
Grams  stain ing  for pus cells  had  17.5% s ensit iv ity  and  h igh 
specificity o f 98.7%. 
PAP s mear had  low sens it iv ity  (12.5%) and  h igh  specificity  in 
d iagnos is o f Trichomonias is. Most o f the Trichomonas pos it ive pat ients 
had  in flammatory  PAP s mear.  
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 Table-31 .Various Inves tigative Procedures  in Diagnosis  of  
Trichomoniasis and their sensi tivi ties  and s peci fici ties . 
Tes ts Sensitivi ty S peci fici ty PPV NPV LR 
pH (>4.5) 82.5 79.1 25.6 98.1 3.95 
Whiff test 60.0 82.4 22.9 96.0 3.41 
Wet  mount  67.7 100.0 86.7 93.75 74.75 
Gram stain  (Pus cells)  17.5 98.7 53.9 93.3 13.4 
PAP s mear (TV +ve) 12.5 100.0 100.0 94.5 -*  
 
 




D. Associated S TD’S  
Majority  o f Trichomoniasis  pat ients  were co in fected  with 
Bacterial Vag inos is (64.3%) in  symptomat ic g roup and (35.7%) in 
asymptomat ic g roup . (The p  value is  0.285) fo llowed  by  Mucopuru lent 
cerv icit is  (p  value is  0.82) and  Candid iasis  (p  value is  0.999) which  is 
stat ist ically not  s ign ificant  when compared to  Trichomonas negat ive 
pat ients. 
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Table-32 . Associated S TD’S  with Trichomoniasis. 
Trichomoniasis 
S ymptomatic As ymptomatic Total   
N %  N %  N %  
Yes  14 70.0 6 30.0 20 100.0 Coexist ing  STI 
No  17 85.0 3 15.0 20 100.0 
Posit ive 9 64.3 5 35.7 14 100.0 Bacterial vag inosis  
Negat ive 22 84.6 4 15.4 26 100.0 
Posit ive 7 87.5 1 12.5 8 100.0 Cerv icit is  
Negat ive 24 75.0 8 25.0 32 100.0 
Posit ive 2 100.0 0 .0 2 100.0 Cand id ias is 
Negat ive 29 76.3 9 23.7 38 100.0 
Posit ive 1 100.0 0 .0 1 100.0 Herpes  
Negat ive 30 76.9 9 23.1 39 100.0 
Posit ive 0 .0 1 100.0 1 100.0 
Negat ive 31 79.5 8 20.5 39 100.0 
HIV in fect ion  
To tal 31 77.5 9 22.5 40 100.0 
 
Figure 27: Coinfections seen in Trichomonas Positive Patients. 
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E. Diagnosis of S tudy Group: 
 The most  common STDs  seen  in  our study  group  was  Bacterial 
Vag inos is (21.6%) fo llowed  by  Mucopuru lent  cerv icit is (16%) and 
Candid ias is (12.8%). 





As ymptomatic group 
N=250  
1.Trichomonas  vag inalis  
2. Bacterial vag inos is 
3. Cand id ias is  
4. MPC 
5. NV 
6. Phys io log ical 
7. HIV 
8. Herpes 
9. Carcinoma cerv ix 
10. Gen ital scab ies  
11. Cerv ical g rowth  
















27 ( 10.8%) 
29 (11.6%) 
26 ( 10.4) 
141 (56.4%) 
13 (5.2%) 







Total 250 250 
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Figure 28: Diagnosis of Trichomonas negative cases in S tudy Group. 
Treatment and Follow up:  A ll the Trichomonas pos it ive 
pat ients  were t reated  with  Tab  Secn idazo le 2gm s ing le dose stat  and 
rev iewed after 7 days , none of the pat ients had recurrence in  our study . 
Partner Treatment: 28partners  of 40women with  Trichomonias is 
was  evaluated  and  all the partners  t reated  with  ep idose (Tab .Secn idazo le 








The p revalence o f Trichomonas vag inalis  in fect ion  varies 
cons iderab ly  in  female popu lat ion  around  worldwide, depend ing  on  the 
popu lat ion stud ied  and  techn iques employed in the d iagnos is. Rang ing 
from 5-74%, the h ighest  rates  reported  among  STI clin ic attendees and 
other h igh-risk popu lat ion .[12,27]  
In  our study  a total o f 8% (40 o f 500women) o f women had 
Trichomoniasis , ie .31 (12.4%) women in  the symptomat ic g roup  and  9 
(3.6%) women in  the asymptomat ic g roup  had  T.vag inalis  infect ion  by 
cu ltu re.The p revalence observed  in  our study  was  comparab le to  study 
done by  Mahmoud  et  al, which  was hosp ital based study  done at  Egypt 
with  a sample size o f 450, o f which  290 were symptomat ic and 160 were 
asymptomat ic. The p revalence o f Trichomonias is in  their study was 
7.7% of which  30(10.34%) were symptomat ic cases  and  3.1% were 
asymptomat ic g roup.[94] 
In  the study  by  Cevah ir et  al, which  included  310 symptomat ic 
pat ients, the p revalence rate o f Trichomonias is was  found  to be 12.9%. 
Th is  is comparab le to  our study  (12.4%) in  symptomat ic g roup .[95]  
Another study done by  Chakaraborthy et al[96]  on both 
symptomat ic and  asymptomat ic pat ients  from rural and  u rban  areas  (102 
cases) at Surat , Ind ia, showed to tal p revalence o f (34.4%) 
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Trichomoniasis  which  is  s ign ificant ly  h igher when  compared  to 
p revalence o f our study  (8%).  
DEMOGRAPHIC CHARACTERS 
AGE 
The p revalence of Trichomonas  vag inalis  has  been  shown to 
increase with age un like in  Chlamydia and  Gonorrhoea.[12]  The 
increased p revalence o f Trichomonal infect ion  in o lder women suggests 
longer durat ion  o f infect iousness  and  the p redominant  asymptomat ic 
natu re o f in fect ion .[2]This was  ev ident  from our study as the mean  age at 
p resentat ion  for women with  T.vag inalis  in fect ion  was  32±7years in 
symptomat ic and 34±9yrs in  asymptomat ic g roup . Th is was comparab le 
with  the popu lat ion  based  study  from Vanuatu, Aust ralia  by  Fot inatos  et 
al,[97]and study  done by  Haythan  et  al[98]  who  reported  a mean  age of 
36.6 years.  However, study by  Dahab et al[99]  reported  a lower mean 
age at  presentat ion  ie .20 to  25yreas. Th is  probab ly  reflects  early  onset 
o f sexual act iv ity in  the h igh-ris k popu lat ion .  
RESIDENCE 
Majority  o f women in  our study  were res id ing  at  u rban  areas 
(67%) and  about  33% women are from rural areas. 
MARITAL HISTORY  
Most  o f the women in  symptomat ic g roup  (74.2%) and  (62.5%) of 
women in  asymptomat ic group  were married  and  25% were s ing le in 
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both  symptomat ic and  asymptomat ic pat ients . The ris k o f in fect ion  is 
more inwomen liv ing  s ing le (16.1%) as  compared  to Trichomonas 
negat ive s ing le women (5.5%). Klinger et  al[58]observed  that  compared 
with  married  women, the risk o f Trichomonias is was s ign ificant ly 
increased among women who are separated, which  is comparab le to  our 
study, though  Trichomonias is  observed  in  majority  o f married  women, 
the p revalence in  separated  women found  to  be more (16.1%) compared 
to  Trichomoniasis negat ive cases in  their study. 
SOCIOECONOMIC STATUS 
About  54.8% of women with  Trichomoniasis  in  our study 
belonged to  lower (class V) socioeconomic status  when compared to 
upper lower (class IV) in  Trichomonas negat ive pat ients. 
EDUCATION STATUS 
Majority  o f women with  Trichomoniasis  in  our study had low 
educat ion  status t ill primary  standard . About  48.7% women stud ied  less 
than  5thstandard  and  35.9% were t ill 6-12th  standard  whereas  most o f the 
Trichomonas negat ive cases had  (52.2%) educat ion  t ill 6-12th  standard. 
However in  the study conducted  by  Haythm .M et  al showed  illiterates 
(61.8%) as majority .[98]  
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HIGH RISK AND BEHAVIOURAL CHARACTERS 
Contraception 
Most o f the Trichomonas pos it ive women and Trichomonas 
negat ive women in  our study  were Tubectomised . However 10.3% of 
Trichomonas posit ive women g ive h isto ry  of at least one ep isode of 
abort ion  when  compared  to  on ly  2% of Trichomonas  negat ive women 
with  h istory  o f abort ion .which  is s ign ificant. 
Pas t H/o PID/infertili ty/veneral  disease 
As  many  as 6 women in  symptomat ic g roup  and  2 women in 
asymptomat ic group  gave h isto ry o f p rev ious venereal d isease in  the 
fo rm of vag inal d ischarge and  two  of the pat ients  in  symptomat ic group 
had  h isto ry  of PID, which is  not  s ign ificant  when  compared  to 
Trichomonas negat ive cases. 
Subs tance abuse 
Only  two  women of Trichomonas  pos it ive cases  in  asymptomat ic 
g roup  had  h isto ry  o f alcoho l abuse and  is not  s ign ificant  and  none o f the 
women in our study indu lged  in s moking .  
Pre and extramarital  contact 
Majority  o f Trichomonas pos it ive cases (45.2%) in  symptomat ic 
g roup  and  50% of women in  asymptomat ic g roup  had  p re and 
ext ramarital contact . When compared  to  8.5% of women in  Trichomonas 
negat ive g roup  which  is  stat istically  s ign ificant . About  7women of the 
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Trichomoniasis in our study g roup were indu lged in  p rost itut ion  as 
compared  to  4women in  Trichomonas negat ive women. 
Hus band having  extramarital  contact 
About  22.6% of Trichomonas  pos it ive pat ients  in  symptomat ic 
g roup  gave h isto ry  o f husband  hav ing  ext ramarital contact , when 
compared  to  on ly  1.25% of women in  negat ive cases, which  is 
stat ist ically s ign ificant . 
S ymptoms in partner 
The h isto ry  suggestive o f Ureth rit is  and  Balan it is  was  p resent  in 
7.7% of men  in  Trichomonas pos it ive cases  and  5.1% of men  had  h istory 
o f dysuria and  p ruritus. 
Sign ifican t ris k facto rs associated  with T.vag inalis  in fect ion in 
our study  were lowsocioeconomic status , a  h isto ry  of p re/ext ramarital 
sexual contact  in the women, husband hav ing extramarital contact, a 
h isto ry o f symptomat ic partner in  the fo rm of dysuria and  u reth ral 
d ischarge that suggest ive o f Trichomonias is in  men . 
 Kaur et  al[26]in  their study  in  North  Ind ia to  assess the p revalence 
o f Trichomonas  vag inalis  infect ion  in  symptomat ic women as  well as  in 
women with  carcinoma cerv ix and  HIV in fect ion  observed  that  being  a 
housewife, belong ing  to  the midd le socioeconomic status  and  non-use of 
cont racept ion  were s ign ifican t ly  associated  with  Trichomonias is. 
Klinger et  al,[58]in  their study to  determine the p red icto rs o f T.vag inalis  
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in fect ion  in  women in  Moshi, Tanzan ia, observed  that  hav ing  a partner 
withT.vag inalis  was the strongest ris k facto r in  women.Other risk 
facto rs  observed  were daily  alcoho l consumpt ion , being  separated, 
hav ing  a partner who  had  ch ild ren  with  other women.  
Sutton  et  al[57]reported that facto rs associated  with  increased 
likelihood o f T.vag inalis  in fect ion in  women in the United States were 
belong ing  to  non-Hispan ic b lack race, a  g reater number o f lifet ime sex 
partners , increas ing  age, lower educat ion  level and  poverty .  
Clinical  characteres tics  
Trichomonas  vag inalis  is  known to  cause persistence o f unt reated 
in fect ion.[100] In our study the mean  durat ion  o f onset  o f symptoms in 
pat ients with  Trichomonias is is  30years and  the mean  durat ion  of 
vag inal d ischarge in  pat ients  with  Trichomonias is  was  4.8months(149 
days ).  
Signs o f in fect ion  in  symptomat ic women include vag inal 
d ischarge (92.5%), frothy fou l s melling d ischarge in  (50%) and 
erythema in  (10%)  women .[8]The characterist ic  featu res  o f the in fect ion 
are p resent in on ly  about  40% to 50% of pat ients.[54] Women with 
T.vag inalis  may  have abdominal pain  due to  salp ing it is  o r endometrit is 
and  postco ital b leed ing  due to  cerv icit is.[101]  
The s igns  and  symptoms  associated  with  the in fect ion  have a 
relat ively  low pos it ive pred ict ive values  fo r Trichomonias is  because of 
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the frequen t occurrence o f these s igns and  symptoms  among  women 
with  other infect ions .[104]  Fouts  et  al [73]  in  their study  on  women 
attend ing  a STI clin ic in  Georg ia demonstrated  that  if the clin ical 
featu res alone were used  to  d iagnose Trichomoniasis , 88% of the 
in fected  women would  be missed  and  29% would  be falsely  ind icated  as 
hav ing  in fect ion .  
In  our study  women with  Trichomoniasis  p resent ing  with  vag inal 
d ischarge, vu lval itch ing  and  lower abdominal pain  was  the most 
frequent ly  reported  symptom, (s ensit iv ity  81.5 %), fo llowed  by  dysuria. 
However, the reported  symptoms  had  low pos it ive p red ict ive values for 
Trichomoniasis . Women with  concurren t Trichomoniasis and other 
in fect ions were more symptomat ic with  h igher frequency  of reported   
itch ing and  lower abdominal pain  as  compared  to  those with 
Trichomoniasis  alone, though  not  stat istically  s ign ificant .  
Among the clin ical s igns in  women with  Trichomonias is, hav ing  a 
p ro fuse vag inal d ischarge, malodorous d ischarge, frothy d ischarge and 
mucopuru lent  o r puru lent  d ischarge were sign ificant ly  associated  with 
Trichomoniasis . Frothy  d ischarge was  observed  in  on ly  58% women in 
our study, but  was the most specific  sign  with  a pos it ive p red ict ive value 
o f 100%. Mucopuru lent  o r puru lent  d ischarge was observed  in  38.7% 
women. Colp it is  macu laris  is a specific  clin ical s ign  for Trichomonas 
in fect ion  but  is  detected  with  reliab ility  on ly  by  co lposcopy  and  rarely 
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by  us ing  rout ine examinat ion.[54]  Co lp it is  macu laris  was  not  observed  in 
any  of the women by  naked  eye examinat ion  in  our study  as  co lposcopy 
was no t done in  our study. 
 Wolner-Hanssen et  al,[102] in  their study on  clin ical 
manifestat ions  o f Trichomonias is done on  women attend ing  a STI clin ic 
observed  that  the frothy  d ischarge was found  in  on ly  8% of women with 
Trichomoniasis  and  had  a specificity  of 99% and  the PPV of 62%; 
co lp it is  macu laris  was  a h igh ly  specific  s ign  (99%) and  had  a h igh  PPV 
(90%), but  was seen  without a co lposcope in  on ly 2 o f the 52 women 
who  had  the find ing  on  co lposcopy. Puru lent  vag inal d ischarge in  their 
study had a specificity  o f 76% and  a PPV of on ly  30%. 
INVESTIGATION  
Cons idering  cu ltu re o f Trichomonas  vag inalis  as  the “go ld 
standard” the sens it iv ity  and  specificity  o f microscop ic and  cyto log ic 
examinat ion  were assessed  
Whiff test  and  pH test ing  are recommended  in  the evaluat ion  of 
vag inal d ischarge and  can  be used as screen ing  methods.[103,104]      
             The pH test ing  was  reported  to  be a h igh ly  sens it ive but  less 
specific  screen ing  too l fo r d iagnosis  o f Trichomonias is.[104]A s imilar 
find ing  was  observed  in  our study , where pH of more than 4.5 had 
82.5% sensit iv ity , and  specificity o f 79.1%.. 
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This  was comparab le to  study done by  Plourd  et  al[105] reported  a 
lower sens it iv ity  o f 70% for pH more than  4.5 in  the d iagnos is  of 
Trichomoniasis . And Whiff test  had  low sens it iv ity (60%) and 
specificity(82.4%), in the d iagnosis  of Trichomoniasis . Whiff test 
pos it iv ity  was  s ign ificant ly  h igher in  the mixed  in fect ion  g roup  as 
compared  to  Trichomonias is  alone because o f the co-occurrence of 
bacterial vag inos is.  
PAP s mear examinat ion had low sensit ive (32.5%) and h igh 
(100%) specificity  in  d iagnos ing  Trichomoniasis. Pus cells in Grams 
stain  had  low sensit iv ity (17.5%) and  h igh  specificity  o f (98.7%). 
WET MO UNT  
Wet mount  using  normal s aline fo r demonst rat ion  of 
Trichomoniais  had  low sensitivity (65%) and high specificity (100%), PPV 
(86.7%), NPV (97%) and LR (74.75%). W et  mount  was  posit ive in  
21 pat ients  and  negat ive in  10 pat ients  in  symptomat ic g roup  and 
pos it ive in  5 and  negat ive in  4 pat ients  in  asymptomat ic g roup .These 
wetmount negat ive pat ient were pos it ive by cu ltu re and none o f the wet 
mount  pos it ive s ample was  negat ive by  cu ltu re. (p  value is  <0.05 and  is 
s ign ificant  in  both  symptomat ic and asymptomat ic pat ients).  
Culture of Trichomonas vaginalis using Diamonds medium 
Cultu re p roved  d iagnos is in all 40 cases of Trichomoniasis with 
100% sens it iv ity  and  specificity . The cu ltu re had  100% sensit iv ity  and 
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specificity  if examined  with  in  3days  o f inocu lat ion . As  compared  to  5th 
day  and  7th  day  where the sensit iv ity  level decreased  to  97.5% and 
77.5% respect ively, however the specificity  remained  100%. 
In  a study  done by  Mohmoud  et  al[94]  (450 cases) cu ltu re 
ident ified  35 (100%) o f cases whereas Wetmount  and  PAP s mear 
d iagnosed  34.2% and  60% of pat ients respect ively  which  is s imilar to 
our study. 
Another study  done by  Cevah ir et  al [95]  showed  that  cu lture was 
pos it ive in  all 40 cases o f Trichomonias is (100%) were as  Wetmount 
was pos it ive on ly  20 (50%) o f cases. 
COINFECTION 
Majority  o f Trichomoniasis  pat ients  were co in fected  with 
Bacterial Vag inos is (64.3%) in  symptomat ic g roup  and  35.7% in 
asymptomat ic g roup  with  a pvalue o f 0.285 which  is  not  stat ist ically 
s ign ificant . The Mucopuru len t  cerv icit is (p  value is  0.821) and 
Candid ias is (p  value is  0.999) were not  stat ist ically  s ign ificant  in  our 
study. 
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Table-34  Comparision between S ymptomatic and As ymptomatic 
Trichomoniasis Posi tive Patients  
 
S ymptomatic 
patients n=31  
As ymptomatic patients 
n=9  
1 .Demographic factors  and high risk behaviours : Is almost similar 
in both the group 
a) Age Mean age is 32 Mean age is 34 
b ) Res idence Urban  women (67%) Urban  women (70%) 
c) Socioeconomic 
status  
Lower class Lower class 
d ) Educat ion  status  Upto  h igher p rimary  Lower p rimary  
e) Marital status Married  women 
(74.2%) 
Married  women (62.5%) 
f) Pre/Extra 
maritalcontact  
Present  in 45% Present  in 50% 
g) Promiscu ity  o f 
partner 
Present  in 62% None 
2 .Clinical  features: 
a. Vag inal d ischarge Moderate to p ro fuse 
fou ls melling 
(64.5%), frothy  
(58%) puru lent  
d ischarge. 
Scanty  to  moderate, 
oudourless d ischarge. 
Fou l s melling  in  
(22.2%), frothy(22%), 
muco id  d ischarge 
b .Vag inal erythema Seen  in  12% of 
women 
None had  erythema 
3 .Inves tigations : 
a) Wetmout   
Posit ive 
Posit ive in  21 
pat ients (67.7%) 
Posit ive in  5 pat ients 
(55.5%) 
Negat ive Negat ive in  10 
pat ients (32.25%) 
Negat ive in  4 pat ients 
(44.4%) 
b ) Cultu re Posit ive in  all 31 
pat ients (100%) 
Posit ive in  all 9 pat ients  
(100%) 
4 . Prevalence of Trichomoniasis in our study: 
Prevalence 12.4% 3.6% 
5 . Ass ociated S TI’s  
Associated  STI’s 70% associated with  
co in fect ions, most 
common being 
Bacterial vag inosis . 
30% associated with  
co in fect ion , most  
common being Bacterial 
vag inos is. 
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SUMMARY 
1) The total p revalence o f Trichomoniasis  in  our study  is  8%. About 
12.4% (31 pat ien ts) in  symptomat ic g roup  and  3.6% (9 pat ients) 
in  asymptomat ic group . 
2) Iso lat ion  o f Trichomonas vag inalis  is  best  done by  Cultu re in 
Diamond’s media on  3rd  day  of inocu lat ion . 
3) Sens it iv ity  and  specificity  o f Culture is  100% in our study. The 
sens it iv ity  o f W et  mount  is  67.7% in  symptomat ic g roup  and 
44.4% in  asymptomat ic group  and  specificity  is  100% in  bo th  the 
g roups. Wet  mount  was negat ive in  14 pat ients (10 in 
symptomat ic, 4 in  asymptomat ic g roup), these wet  mount  negat ive 
sample were pos it ive by  cu ltu re. Thus cu ltu re is  cons idered  as 
go ld  standard  invest igat ion  fo r Trichomonias is. 
4) Other Invest igat ive p rocedures:  
a . The pH > 4.5 had  sensit iv ity o f 82.5% and  specificity  o f 79.1% 
in  d iagnos ing  Trichomonias is.  
b . Whiff test  had  sensit iv ity  o f 60% (which  was  comparab le to 
wet  mount) and specificity  o f 82%. 
c. PAP s mear had  low sens it iv ity  (12.5%) and  h igh  specificity  in 
d iagnos is o f Trichomoniasis .  
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d . The Gram’s  stain ing  fo r pus cells  had  17.5% sens it iv ity  and 
98.7% specificity . 
5) Demograph ic and  socio -economic facto rs  o f Trichomonias is 
pat ients derived from our study are:  
a . Trichomoniasis  seen  commonly  in  age g roup  o f 30 ± 4 years 
both  in  symptomat ic and  asymptomat ic pat ients. 
b . Most  o f the Trichomonas  posit ive women in  our study  were 
res id ing  in  u rban  areas  and  belongs  to  lower (class V) 
socioeconomic status  and  had  low educat ional status. 
6) Clin ical characterist ics o f Trichomonas pos it ive pat ients derived 
from our study are: 
a . The mean  durat ion  o f onset  o f symptoms  is  30 years  and  mean 
durat ion  o f vag inal d ischarge was  4.8 months  (149 days) in 
symptomat ic women. 
b . The most common s igns and  symptoms  of Trichomonias is 
women  in  symptomat ic g roup  are vag inal d ischarge (92.5%), 
frothy  fou l s melling  d ischarge (58%). The other common 
symptoms  seen  along  with  vag inal d ischarge are vu lval itch ing, 
LAP and  dysuria. The characterist ic  featu res o f the in fect ion 
are seen  on ly  in  about  40% to  50% of pat ients .  
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c. The d ischarge characterist ics commonly  seen  in  asymptomat ic 
pat ients are scan ty to  moderate, odourless, muco id  d ischarge. 
7) Ris k facto rs associated with  Trichomonias is in  our study  are:  
a . Women with  low socioeconomic status and  res id ing  in u rban 
areas. 
b . Women who  were s ing le and  separated  from their husband . 
c . Women with mult ip le sexual partner and  
d . Women whose husband hav ing  ext ramarital con tact . 
8) The most  common co in fect ion  with  Trichomoniasis  in  our study  is 
Bacterial Vag inos is and Cerv icit is . 
9) There was  no  associat ion  between  Trichomonias is  and  HIV in  our 
study. (out  o f  9 pos it ive  HIV cases in the study  g roup ,one 
pat ient  in asymptomat ic g roup  was d ignosed  as Trichomonis is) 
10) There was also no  associat ion  between  Trichomonias is and 
cerv ical cancer in our study. (In the age g roup o f 40-55yrs , 5 
pat ients  in  symptomat ic g roup  with  cerv ical cancer were negat ive 
fo r Trichomonas vag inalis ). 
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CONCLUSION 
 The Prevalence of Trichomoniasis in Symptomatic Group is 12.4%. 
 The Prevalence of Trichomoniais in Asymptomatic Group is 3.6%. 
 Cultu re is  the go ld standard  investigat ion in the d iagnosis  of   
Trichomoniasis  with sens it iv ity  and  specificity  of 100%. 
 Wet mount  had  low sens it iv ity  and  h igh  specificity  in  our study. 
Wet  mount  failed  to  ident ify  14 cases which  was  pos it ive by 
cu ltu re (p  value is  <0.05). 
 Rout ine use o f W et  mount  so lely  for the d iagnos is  of 
Trichomoniasis  leads  to  false negat ive resu lts , hence cu lture must 
be rout inely  done whenever Wetmount  is negat ive and 
Trichomoniasis  is st rong ly suspected . 
 Clin ical characterist ics o f symptomat ic pat ients are moderate to 
p ro fuse fou l s melling frothy  mucopuru lent  vag inal d ischarge, 
when  compared  to  scanty , moderate odourless muco id  d ischarge 
o f asymptomat ic pat ients.  
 Ris k facto rs associated  with  Trichomonias is  are women with low 
socioeconomic status, who  are s ing le, separated  from their 
husband , hav ing  mult ip le sexual partners and  women whose 
husband  has ext ramarital contact. 
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ABBREVIATIONS 
AC : Adenocarcinoma 
AGNOS : Atyp ical g landu lar cells  not  otherwise 
specified  
AP : Adhes in  pro teins 
 BV : Bacterial vag inosis  
CDC  : Cen ter o f Disease cont ro l 
CPE : Cytopatho log ical Effects  
FCU : First  catch  u rine 
Gm  : Grams  
HGSIL : High  g rade squamous  int raep ithelial les ion  
HIV : Human  Immunodeficiency Virus  
IL : Interleukin  
KOH : Potassium hydroxide 
LSCS : Lower segment  ceaserean  sect ion  
LR : Likelyhood  rat io  
MPC : Mucopuru lent cerv icit is  
NACO : Nat ional AIDS contro l o rgan izat ion  
Paps s mear : Papan ico laou  s mear 
SCC : Squamous cell carcinoma 
SD : Standard  dev iat ion  
Sn : Sens it iv ity  
Sp : Specificity  
sp : Species 
STI : Sexually  t rans mitted  in fect ions 
TV : Trichomoniasis  
T.vag inalis : Trichomonas vag inalis  
TNF α : Tumor necros is facto r alpha 
TLR : To ll-like recepto r 
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S peculum examination: Profuse Mucoid Discharge 
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MATERIALS  REQUIRED FOR DIAMOND’S MEDIA 
PREPARATION 
 




PREPARED MEDIUM INCONICAL GLAS S JAR 
 
15ML CAPACITY CAPPED GLASS TUBES  CONTAINING 




GROSS APPEARANCE OF  TRICHO MONAS  POS ITIVE S AMPLE 
 





PATIENT CONSENT FORM 
 
Title of the study:-“  Comparative study of Trichomonasvaginalis infection in symptomatic 
and asymptomatic female patients attending STD outpatient dept  diagnosed by wet mount 
and culture method. 
 
 
Name of the Participant: 
______________________________________________________. 
Name of the Principal (Co-Investigator): Dr ANUPAMA.M.P 
Name of the Institution: Government General Hospital, Chennai. 
Documentation of the informed consent 
I _____________________________ have read the information in this form (or it has been 
read  
to me). I was free to ask any questions and they have been answered. I am over 18 years of 
age  
and, exercising my free power of choice, hereby give my consent to be included as a 
participant  
in the study.. 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. My rights and responsibilities have been explained to me by the investigator. 
5. I agree to cooperate with the investigator and I will inform him/her immediately if I suffer 
unusual symptoms. 
6. I have not participated in any research study within the past _________month(s). 
7. I am aware of the fact that I can opt out of the study at any time without having to give any 
reason and this will not affect my future treatment in this hospital. 
8. I hereby give permission to the investigators to release the information obtained from me 
as 
result of participation in this study to the sponsors, regulatory authorities, Govt. agencies, and 
IEC. I understand that they are publicly presented. 
9. My identity will be kept confidential if my data are publicly presented 
10. I am aware that if I have any question during this study, I should contact at one of the 
addresses listed above. By signing this consent form I attest that the information given in this 
document and the HIV consent form has been clearly explained to me and apparently 
understood by me, I will be given a copy of this consent document. 
                                                                                                     Participant’s Initials: 
__________ 
For adult participants: 
Name and signature / thumb impression of the participant (or legal representative if 
participant incompetent) 
_______________                 _________________                   _______________ 
Name                                      Signature                                     Date 
Name and Signature of impartial witness (required for illiterate patients): 
_______________                _________________                    _______________ 
Name                                     Signature                                      Date 
Address and contact number of the impartial witness: 
Name and Signature of the investigator or his representative obtaining consent: 
_______________               _________________                   _______________ 










Serial No : 
STD OP No  : 
Name :  
Sex  :               






Address:  Rural/Urban 
 












Education Status:           Illiterate 
<5th 





          Marital status:      Married / Single/widow 
Married since: <5years 
5-10 years 
11-15 years 




Premarital Contact : Yes  / No  
 
If yes   Commercial  sexworker 
Homosexual 
  Transgender 
Known person 
 
Extra marital contact:      Yes/ No 
 




                                                 Transgender 
 










Contraceptive followed: Oral 
 Condom /Shield 
 IUD 
 No contraceptive followed 
Previous history of sexually transmitted infection:   Yes/ No 
If yes                          Genital ulcer 
 Genital discharge 
 Others 
Whether diagnosed properly and took appropriate treatment:  Yes /   No 




C/O Genital ulcer  
C/O Genital discharge 
Duration history 
Others if specify 
H/O Itching over genitalia 
H/O swelling in inguinal region 
H/O burning micturition 
H/O oral lesion 
H/O lower abdominal pain 
H/O Dyspareunia 
H/O Dysmenorrhoea 
Menstrual H/O: Regular/Rrregular/Relation to discharge present or absent. 
Obstetric H/O: Normal delivery/ LSCS/Abortion/Nullipara. 
 
Past history: 
TB, BA, any major illness. 
H/O blood transfusions and any major surgeries. 
Previous history of venereal diseases. 
 
Personal history: 
H/O alcohol intake. 
H/O smoking. 
H/O IV Drug abuse. 
 
General Examination: 
Pallor, Icterus, Cyanosis, Clubbing ,lymphadenopathy 















Examination Inguinal lymphnode.  
 
 












In case of genital ulcers: 
 
Dark field examination for Treponema pallidum.  
 
Tzanck test for  multi nucleated gaint epithelial cells. 
 
Gram stain for Haemophilus ducreyi  and Candida. 
 
Tissue smear and Leishman’s stain for klebsiella granulomatis. 
 
 In case of vaginal discharge: 
Wet mount microscopy for Trichomonas vaginalis. 
Culture for Trichomonalis vaginalis. 
10% KOH preparation for Candida albicans. 
Gram stain of vaginal smear for clue cells and  Candidal hyphae. 
Gram stain of endocervical smear for gonococci. 
In addition to above investigation endocervical swab for gonococcal culture and 
for PAP smear are collected for all female patients.  










































































































































































































































































































































































































































































































































































































































































































1 45 2 3 1 2 2 3 1 1 1 1 4 1 1 35 7 1 6 1 1 2 3 2 4 2 2 1 2 1 2 1 6 1 P P P N N NO TV
2 26 1 4 1 1 1 3 1 1 1 1 3 1 1 25 365 1 3 1 1 2 1 1 3 1 1 1 2 1 2 1 1 2 P P N N N YES TV/BV
3 46 2 1 1 1 1 3 1 1 1 1 4 1 1 46 10 1 6 1 1 2 1 1 3 1 1 1 1 1 1 1 6 1 N N N N N NO UTI
4 32 1 2 2 1 1 3 1 1 1 1 4 1 1 32 8 2 7 1 1 2 3 1 3 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
5 18 1 1 1 1 1 2 1 1 1 1 3 1 1 18 7 1 1 1 1 2 3 1 1 1 1 1 1 1 1 2 6 1 N N N N N NO CAN
6 29 2 3 1 2 1 4 1 1 4 1 4 1 1 28 365 1 7 1 1 2 1 1 3 1 5 1 1 1 1 2 3 1 N N N N N NO CAN
7 50 1 1 2 1 1 3 1 1 1 1 4 1 1 50 7 1 1,3 1 1 2 3 1 3 3 1 2 1 1 1 1 2 1 N N N N N NO BV
8 33 1 3 2 1 1 3 1 1 1 1 3 1 1 32 365 2 1 1 1 2 1 1 1 1 1 1 1 1 1 2 6 1 N N N N p NO CAN
9 30 1 2 2 1 1 3 2 2 1 1 4 1 1 29 365 1 6 1 1 2 1 1 3 1 1 1 1 1 3 2 5 1 N N N N N NO CAN
10 24 2 3 2 2 1 4 1 4 4 1 4 1 1 24 60 2 6 1 1 2 1 1 2 1 5 1 1 1 1 1 6,1 1 N N N N N NO PHY
11 44 1 3 1 1 1 3 1 5 1 1 4 1 1 42 720 1 6 3 1 1 1 2 3 1 1 1 1 1 1 1 1 1 N N N N N NO LC
12 37 1 1 2 1 1 3 1 1 1 1 4 1 1 37 30 1 6 1 1 2 2 1 2 1 1 1 1 1 1 1 1 1 N N N N N NO PHY
13 40 2 2 1 1 1 1 1 1 1 1 4 1 1 40 180 2 6 1 1 2 3 2 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV
14 20 1 2 2 1 1 3 1 5 1 1 4 1 1 19 365 1 6 1 1 2 2 1 1 1 1 1 1 1 3 2 5 1 N N N N N NO CAN
15 35 1 4 1 1 1 1 1 1 1 1 4 1 1 35 30 1 3 1 1 2 2 2 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV
16 35 2 1 1 1 1 3 1 1 1 1 4 1 1 36 210 1 5 1 1 2 3 2 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV
17 50 1 2 2 1 1 1 1 1 1 1 4 1 1 48 150 1 6 1 1 2 3 1 3 1 1 1 2 2 1 2 1,5 1 N N N N N NO BV/CAN
18 27 2 3 0 1 1 1 1 1 1 1 4 1 1 22 4yrs 1 3 1 1 2 2 1 1 1 1 1 1 1 3 2 5 1 N N N N N NO CAN
19 27 1 3 2 1 1 1 1 1 1 1 4 1 1 27 90 1 1,3 1 2 2 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
20 35 2 3 2 1 2 1 1 1 1 1 3 1 1 35 30 1 1,3 1 1 2 2 2 4 3 1 1 2 1 2 1 6 1 P P P N N NO TV
21 40 1 4 0 1 1 1 1 1 2 1 4 1 1 40 15 1 1 1 1 2 1 1 3 2 1 1 2 2 4 1 1 1 N N N N n NO BV
22 36 2 3 2 1 1 3 1 1 1 1 4 1 1 33 3y 1 1,3,5 2 1 2 2 1 3 1 1 1 1 1 3 2 5 1 N N N N N NO CAN
23 31 1 4 2 1 1 3 1 1 1 1 4 1 1 31 180 2 2,3 1 1 2 2 3 2 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
24 27 1 3 1 1 1 1 1 1 2 1 4 1 1 21 7y 2 3 1 1 2 3 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
25 32 2 4 0 1 1 2 1 1 1 4 4 1 1 30 2y 1 1 1 1 2 3 3 4 1,3 1 1 2 2 2,4 1 1,5 1 P P N N N YES TV/BV
26 39 1 4 2 1 1 1 1 1 1 1 4 1 1 39 3 1 2 3 1 2 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO PHY/BC
27 22 2 3 3 2 2 2 2 4 4 3,4 4 1 1 22 7 1 2,3 2 2 2 2 2 2 3 5 1 1 1 1 1 3 1 N N N N N NO HERPES
28 40 1 3 2 1 1 1 1 1 1 1 4 1 1 38 60 1 3 1 1 2 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
29 30 1 4 0 1 1 1 1 1 1 1 4 1 1 30 20 1 6 1 1 2 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
30 23 2 3 2 1 1 1 1 1 1 1 4 1 1 20 3Y 2 6 1 2 2 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
31 19 1 4 2 2 1 4 1 4 4 1 4 1 1 16 728 2 6 1 1 2 2 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO MPC
32 34 1 3 2 1 1 1 1 3 1 1 4 1 1 34 30 1 1 1 1 2 1 1 5 1 2 1 1 1 1 1 3 1 N N N N N NO PHY
33 30 2 4 1 1 1 1 1 1 1 1 4 1 1 28 30 1 3 1 1 2 2 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
34 28 1 3 2 1 1 1 1 1 2 1 4 1 1 26 20 2 1 1 1 2 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
35 45 1 3 0 1 1 1 1 1 2 1 4 1 1 44 365 1 1,3 7 2 2 2 3 1 1 2 1 1 1 1 1 4,5 1 N N N N N NO CAN
36 27 2 2 2 1 1 1 1 1 1 1 4 1 1 29 90 1 6 1 1 2 2 1 1 1 1 1 1 1 1 1 3,4 1 N N N N N NO MPC
37 35 1 2 1 1 1 1 1 1 1 1 4 4 1 35 25 2 6 1 1 2 1 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
38 23 1 2 2 1 1 3 1 2 2 1 4 1 1 23 25 2 1 1 2 2 1 1 1 1 1 1 1 2 3 2 4,5 6 N N N N N NO CAN
39 35 2 3 2 1 1 1 1 1 1 1 4 1 1 35 15 2 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
40 40 1 3 2 1 1 1 2 1 1 1 4 1 1 40 20 1 8 3 2 2 1 1 2 1 2 1 1 1 1 1 3,4 1 N N N N N NO MPC
41 22 1 1 2 1 1 1 1 1 1 1 4 2 1 22 30 2 1,3 1 1 2 1 1 3 2 1 1 2 2 4 1 1,2 1 N N N N N NO BV
DIAGNOSIS
SYMPTOMATIC PATIENTS
































































































































































































































































































































































































































































































































































































































































































































DEMOGRAPHIC, BEHAVIOUR AND REPRODUCTIVE HISTORY INVESTIGATIONS
42 39 2 3 3 1 1 1 1 1 1 1 4 1 1 38 20 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 N N N N N NO PHY





















































































































































































































































































































































































































































































































































































































































































































DEMOGRAPHIC, BEHAVIOUR AND REPRODUCTIVE HISTORY INVESTIGATIONS
44 33 1 1 1 1 1 1 1 1 1 1 4 1 1 33 365 1 1 1 1 2 2 1 3 1 1 1 1 2 3 2 5 1 N N N N N NO CAN
45 38 1 3 3 1 1 1 1 1 1 1 4 1 1 38 20 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 N N N N N NO PHY
46 32 1 3 2 1 1 1 1 1 2 1 4 1 1 32 20 1 3 1 1 2 1 1 1 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
47 30 1 2 1 1 1 1 1 1 2 1 4 1 1 30 15 1 1 1 1 2 2 1 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV
48 28 1 3 3 1 1 1 1 2 1 1 4 1 1 28 7 2 6 1 1 2 2 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
49 36 1 3 0 1 1 1 1 1 1 1 4 1 1 30 15 1 1 1 1 2 3 3 1 1 1 1 1 2 3 2 5 1 N N N N N NO CAN
50 30 2 3 0 1 1 1 1 2 3 5 3 1 1 30 60 2 3 1 1 2 2 3 4 3 1 1 2 2 2,4 1 1 1 P P P N N YEStv/bv TV/BV
51 26 1 3 1 1 1 1 1 2 1 1 1 1 1 26 7 1 6 1 1 2 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
52 32 1 3 0 1 1 1 1 1 1 1 4 1 1 30 15 1 1 1 1 2 3 3 1 1 1 1 1 2 3 2 5 1 N N N N N NO CAN
53 30 1 3 3 1 1 1 1 1 1 1 4 1 1 38 20 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 N N N N N NO PHY
54 25 2 2 1 1 1 1 1 1 1 1 4 1 1 24 15 2 6 1 1 2 1 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
55 40 1 1 5 2 2 4 2 4 3 1 3 1 1 38 7 2 1 1 1 2 3 2 4 1 2 1 1 2 2 1 1 1 P P N N N YES TV/BV
56 40 1 2 1 1 1 1 1 1 1 1 4 1 1 40 10 1 6 1 1 2 1 1 2 1 2 1 1 1 1 1 6 1 N N N N N NO PHY
57 48 2 3 2 1 1 1 1 1 1 2 4 1 1 48 30 7 2 2 1 2 2 2 1 1 2 2 2 1 1 1 3,4 1 N N N N N NO MPC
58 54 1 3 2 1 2 3 2 2 1 1 4 1 1 54 2 1 1 1 1 2 2 3 1 1 1 1 1 2 3 2 5,4 1 N N N N N NO CAN
59 37 1 2 2 1 1 1 3 1 1 1 4 1 1 37 15 1 8 1 1 2 1` 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO BC/PHY
60 52 1 3 2 1 1 1 1 1 1 1 4 1 1 40 7 1 1 1 2 1 1 2 1 1 2 1 1 1 1 1 6 1 N N N N N NO PHY
61 40 1 3 1 1 1 1 1 1 1 1 4 1 1 40 14 1 6 1 1 2 1 1 1 1 1 1 1 1 1 1 11 1 N N N N N NO PHY
62 34 1 2 1 1 1 1 1 1 1 1 4 4 1 33 15 2 6 1 1 2 1 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
63 52 1 2 1 1 1 1 1 1 2 1 4 1 1 45 6m 1 1 1 1 2 2 1 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV
64 40 1 3 3 1 1 1 1 1 1 1 4 1 1 40 20 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
65 34 1 4 2 1 1 1 2 2 1 1 4 1 1 33 45 1 6 1 1 2 3 1 5 3 1 1 2 1 2 1 6 1 P P N N N NO TV
66 49 1 2 2 1 2 3 2 1 1 3 4 1 1 40 7 2 1,3 1 1 2 2 2 4 3 1 1 2 2 2 1 4 1 P P P N N YES TV/MPC
67 25 1 2 2 1 1 3 1 1 1 6,3 4 1 1 24 7 1 1,7 4 2 2 2 1 5 1 1 1 1 1 1 2 5 1 N N N N P NO SY2/CAN
68 20 1 2 1 2 2 4 1 4 4 6 4 1 1 19 60 2 3 1 1 1 1 1 2 1 2 1 1 1 1 1 6 1 N N N N N NO PHY
69 26 1 3 1 1 1 3 1 2 3 1 4 1 1 26 90 2 1 1 2 1 1 1 5 1 1 1 2 2 2,4 1 1 1 P P P N N NO TV/BV
70 50 2 2 2 1 1 1 1 1 1 1 4 1 1 50 30 1 1,2 2 1 2 1 1 3 2 1 1 2 2 4 1 1 1 N N N N P NO BV/SY
71 55 1 3 2 1 1 1 1 1 1 1 4 1 1 55 7 1 6 1 1 2 2 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
72 39 1 2 1 1 1 1 1 1 1 1 4 1 1 39 14 1 6 1 1 2 1 1 6 1 2 1 1 1 1 1 4,3 1 N N N N N NO MPC
73 35 1 3 1 1 1 1 1 1 1 1 4 1 1 34 15 1 6 1 1 2 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
74 28 2 2 0 1 1 1 1 1 1 1 4 1 1 27 6 2 1 1 2 2 2 1 3 2 1 1 2 2 4 1 1,4 1 N N N N N NO MPC/BV
75 36 1 3 2 1 1 1 1 1 1 1 4 1 1 36 30 1 6 1 1 2 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
76 29 1 4 1 1 1 1 1 1 1 1 4 1 1 29 7 1 6 1 1 2 1 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
77 22 1 2 2 1 1 1 1 1 1 1 4 1 1 22 15 1 1 1 1 2 2 2 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV
78 30 1 4 1 1 1 1 1 1 1 1 4 2 1 30 7 1 1 1 1 2 1 1 6 1 2 1 1 1 1 1 4 1 N N N N N NO MPC
79 34 1 3 2 1 1 1 1 1 4 6 4 1 1 30 1y 2 1,3 3 1 2 2 2 3 3 5 1 2 2 1 1 3.4 1 N N N P N NO VERRUCOUS HSV/HIV
80 28 1 4 0 1 1 1 1 1 1 1 4 1 1 28 15 1 6 1 1 2 1 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
81 30 1 4 1 1 1 1 1 1 1 1 4 1 1 30 30 1 6 1 1 2 1 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
82 39 1 2 2 1 1 1 1 1 1 1 4 1 1 39 7 1 1 1 1 2 2 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
83 34 2 3 2 1 1 1 1 1 1 6 4 1 1 34 60 1 6 2 1 2 2 1 2 2 1 1 2 2 4 2 1 1 N N N P N NO BV/HIV





















































































































































































































































































































































































































































































































































































































































































































DEMOGRAPHIC, BEHAVIOUR AND REPRODUCTIVE HISTORY INVESTIGATIONS
85 31 1 3 2 1 1 1 1 3 1 1 4 1 1 31 15 1 6 1 1 2 3 1 2 2 1 1 2 1 4 2 1 1 N N N N N NO BV





















































































































































































































































































































































































































































































































































































































































































































DEMOGRAPHIC, BEHAVIOUR AND REPRODUCTIVE HISTORY INVESTIGATIONS
87 45 1 3 1 1 1 1 1 1 1 1 4 1 1 45 7 1 6 1 1 2 1 1 1 1 1 1 1 1 3 2 5 1 N N N N N NO CAN
88 28 1 2 1 1 1 1 1 1 1 1 4 1 1 28 14 1 1 1 1 2 3 1 6 3 2 1 1 1 1 1 4,3 1 N N N N N NO MPC
89 38 1 2 2 1 1 1 1 1 1 1 4 1 1 37 15 1 1 1 1 2 2 2 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV
90 25 1 3 1 1 1 1 1 1 1 1 4 1 1 20 30 1 6 1 1 2 1 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
91 23 1 4 3 1 1 1 1 1 1 1 4 1 1 19 3m 1 6 1 1 2 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
92 20 1 3 2 1 1 1 1 1 1 1 4 1 1 20 25 1 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
93 22 1 4 1 1 1 1 1 2 2 1 4 1 1 22 10 1 1 1 1 2 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
94 40 2 3 1 1 1 1 1 2 2 1 4 1 1 40 1m 1 6 1 1 2 1 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
95 28 1 3 2 1 1 1 1 3 1 1 4 1 1 28 15 1 1,2 1 1 2 3 1 2 2 1 1 2 2 4 2 1 1 N N N N N NO BV
96 18 1 4 1 1 1 1 1 2 2 1 4 1 1 18 15 1 6 1 1 2 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
97 24 1 4 1 1 1 1 1 2 2 1 4 1 1 24 1m 1 1 1 1 2 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
98 40 1 3 2 1 1 1 1 3 1 1 4 1 1 40 15 1 1,2 1 1 2 3 1 2 2 1 1 2 2 4 2 1 1 N N N N N NO BV
99 55 1 3 3 1 1 1 1 2 1 1 4 1 1 55 3m 1 1 1 1 2 2 2 1 1 1 1 1 1 3 2 6 1 N N N N N NO CAN
100 20 1 3 1 1 1 1 1 2 2 1 4 1 1 35 5m 1 1 1 1 2 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
101 39 1 3 1 1 1 1 1 2 2 1 4 1 1 35 5m 1 1 1 1 2 21 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
102 30 1 2 1 1 1 3 1 2 1 1 4 1 1 30 25 1 1,2 1 1 2 1 3 1 1 1 1 1 2 3 2 5 1 N N N N N NO CAN
103 40 1 3 1 1 1 3 1 1 1 2 4 1 1 40 1m 1 1 1 1 1 3 2 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV
104 26 1 4 2 1 1 1 1 3 1 1 4 1 1 26 30 1 6 1 1 2 1 2 4 3 2 1 2 2 1 1 6 1 N N N N N NO PHY
105 28 1 4 2 1 1 1 1 1 1 1 4 1 1 28 45 1 6 1 1 2 3 1 5 3 1 1 2 1 2 1 6 2 P P P N N NO TV
106 28 1 4 1 1 1 1 1 1 1 1 4 1 1 26 2y 2 1,3 1 1 2 2 2 5 1 1 1 2 1 2 1 4 1 P P P N N YES TV/MPC
107 40 1 3 2 1 1 1 1 1 1 1 4 1 1 40 5 1 6 1 1 2 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
108 41 1 3 2 1 1 3 1 1 2 1 4 1 1 40 20 1 1,3 1 1 2 2 1 4 1 1 1 1 1 2 1 2 2 P P N N N YES TV/MPC
109 28 1 3 2 1 1 1 3 1 1 2 1 4 1 28 14 1 7 1 2 2 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO HERPES
110 40 1 3 1 1 1 3 1 1 1 5 3 1 1 39 1y 1 1 1 1 2 1 1 2 1 1 1 1 1 1 1 6 1 P P N N N NO TV
111 37 1 3 1 1 1 1 1 2 2 1 4 1 0 35 5m 1 1 1 1 2 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
112 48 2 3 5 1 1 1 1 1 1 1 3 1 1 40 365 1 3 1 1 1 1 2 3 1 1 1 2 2 4 1 1 1 N N N N N NO BV
113 35 1 3 1 1 1 2 1 1 1 1 4 1 0 35 14 2 3 2 1 2 2 2 4 1 1 1 2 1 1 1 1 1 P P P N N YES TV/BV
114 45 1 3 1 1 1 1 1 1 1 1 1 1 1 45 60 1 3 1 1 1 2 1 5 1 1 2 1 1 1 1 4 1 N N N N N NO MPC
115 44 1 3 1 1 1 1 1 1 1 7 4 1 1 44 6m 2 1 1 1 2 2 2 1 2 1 1 1 1 1 1 6 1 N N N N N NO PHY
116 50 2 4 1 1 2 1 2 1 1 6 4 1 1 50 90 1 1,5 2 1 2 1 2 1 3 2 2 1 1 1 1 4,3 7 N N N N N NO CACERVIX
117 40 1 4 0 1 1 3 1 4 4 3 2 1 1 30 30 2 8 1 1 1 2 2 4 1 1 1 2 2 2 1 4 2 P P P N N YES TV/MPC
118 38 1 3 1 1 1 1 1 1 2 1 4 1 1 38 1m 1 1,3 1 2 2 2 1 6 2 1 1 1 1 1 1 3,4 1 N N N N N NO MPC
119 35 1 3 1 1 1 1 1 2 2 1 4 1 0 35 5m 1 1 1 1 2 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
120 20 1 2 2 1 1 1 1 1 2 1 4 1 1 20 3y 1 6 1 1 1 2 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
121 26 2 3 1 1 1 1 1 2 2 1 4 1 0 35 5m 1 1 1 1 2 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
122 55 1 3 0 1 1 1 1 1 1 1 4 1 1 55 1m 1 2 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
123 30 1 2 1 1 1 3 1 1 4 1 4 1 1 30 15 1 1 1 1 2 3 2 3 1 1 1 2 2 4 2 6 1 N N N N N NO BV
124 21 1 4 2 1 2 2 4 2 4 4 1 4 1 18 60 2 1,3 1 1 2 2 2 4 1 1 1 2 2 1 3 1 2 P P N N N YES TV/BV
125 45 1 2 1 1 1 3 1 2 1 1 4 1 1 52 1 1 1,2 1 1 2 1 3 1 1 1 1 1 2 4 2 5 1 N N N N N NO CAN
126 17 1 4 2 2 2 4 2 4 4 1 4 1 1 16 365 2 6 1 1 2 3 2 4 1 5 1 2 2 2 1 1,3 1 P P P N N NO TV





















































































































































































































































































































































































































































































































































































































































































































DEMOGRAPHIC, BEHAVIOUR AND REPRODUCTIVE HISTORY INVESTIGATIONS
128 38 1 3 1 1 1 1 1 1 2 1 4 1 1 33 2y 12 1 1 2 2 1 2 6 2 1 1 1 1 1 1 3,4 1 N N N N N NO MPC





















































































































































































































































































































































































































































































































































































































































































































DEMOGRAPHIC, BEHAVIOUR AND REPRODUCTIVE HISTORY INVESTIGATIONS
130 39 1 3 2 1 2 2 1 1 2 2 4 1 1 39 7 2 2,3 1 1 2 2 1 6 1 1 1 2 2 2 2 6 2 P P P N N NO TV
131 32 1 2 1 1 1 3 1 1 4 1 4 1 1 32 15 1 1 3 1 2 3 2 3 1 1 1 2 2 4 2 6 1 N N N N N NO BV
132 28 1 4 1 2 2 4 2 4 4 1 4 1 1 28 6m 2 6 1 1 2 3 2 4 1 5 1 2 2 2 1 1,3 1 P P P N N NO TV
133 39 1 2 1 1 1 3 1 1 4 1 4 1 1 39 1m 1 1 1 1 2 3 2 3 1 1 1 2 2 4 2 6 1 N N N N N NO BV
134 36 2 3 1 1 1 1 1 2 2 1 4 1 0 36 3m 1 1 1 1 2 2 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
135 42 1 2 1 1 1 3 1 1 4 1 4 1 1 40 1y 1 1 1 1 2 3 2 3 1 1 1 2 2 4 2 6 1 N N N N N NO BV
136 50 2 3 2 1 1 1 1 1 2 1 4 1 1 48 2y 1 3 1 1 2 3 1 3 1 1 1 2 2 4 1 1 1 N N N N N NO BV
137 19 2 3 1 1 1 3 1 1 2 1 4 2 1 16 5 1 1,3 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
138 25 1 3 1 1 1 4 1 1 1 1 4 1 1 24 30 1 6 1 1 2 1 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
139 23 1 4 1 1 1 3 1 1 2 1 4 2 1 20 30 1 1 1 1 2 3 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
140 37 2 2 2 1 2 1 1 1 1 4 1 1 1 37 60 1 1 2 2 1 2 2 2 2 1 1 1 2 1 1 1 1 N N N N N NO BV
141 32 1 4 2 1 2 2 4 2 4 4 1 4 1 32 60 2 1,3 1 1 2 2 2 4 1 1 1 2 2 1 3 1 1 p p N N N YES TV/BV
142 30 1 4 1 2 2 4 2 4 4 1 4 1 1 29 365 2 6 1 1 2 3 2 4 1 5 1 2 2 2 1 1,3 1 p p p N N NO TV
143 46 1 3 1 1 1 4 1 1 1 1 4 1 1 45 30 1 6 1 1 2 1 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
144 28 1 3 2 1 1 1 1 1 1 1 4 1 1 16 8y 1 3 1 1 2 1 1 5 1 2 2 2 1 1 1 3 1 N N N N N NO MPC
145 20 1 3 3 1 1 1 1 1 1 1 4 1 1 60 7 1 8 1 1 2 2 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO NV
146 26 1 3 2 1 1 1 1 1 4 6 4 1 1 23 3y 2 3,2 1 1 2 2 1 2 1 1 1 1 1 1 2 3,4 1 N N N N N NO MPC
147 28 1 2 1 1 1 1 1 2 1 1 4 1 1 28 90 1 3,2 1 1 2 2 2 5 2 2 1 1 1 1 1 3,4 1 N N N N N NO MPC
148 45 2 3 1 1 1 1 1 2 6 4 4 1 1 45 10 1 3 1 1 2 2 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO LAP
149 50 2 3 1 1 1 3 1 1 1 1 4 1 1 50 90 1 3 1 1 2 2 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO NV
150 28 2 3 2 1 1 1 1 1 2 4 4 1 1 28 3m 1 6 1 1 2 1 1 5 1 2 1 2 2 1 1 1 1 N N N N N NO MPC
151 28 1 4 1 2 2 4 2 4 4 1 4 1 1 28 20 2 1 1 1 2 3 2 6 1 5 1 2 2 2 1 1,3 1 P P P N N NO TV
152 50 1 2 0 1 1 1 1 1 1 1 4 1 1 48 27 1 1,3 3 1 2 2 2 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV/BC
153 29 2 2 2 1 1 1 1 1 1 1 4 1 1 28 10 1 1.3 1 1 2 1 1 5 1 2 1 2 1 4 1 1,3 1 N N N N N NO BV/MPC
154 29 1 2 1 1 1 1 1 1 1 1 4 1 1 18 80 2 1,2 1 1 2 2 2 4 3 2 2 2 2 2,4 1 4,3 1 P P N N N YES TV/MPC/HSV
155 45 1 4 0 1 1 1 1 2 1 1 4 1 1 52 7 1 1 1 2 1 1 1 1 1 1 1 1 2 3 2 3 1 N N N N N NO CAN
156 40 1 2 1 1 1 3 1 1 4 1 4 1 1 39 1y 1 1 1 1 2 2 1 2 1 1 1 2 3 2 2 6 1 N N N N N NO CAN
157 26 2 2 1 1 1 1 1 2 2 6 4 1 1 26 60 2 8 1 1 2 2 1 4 2 1 1 2 1 4 1 1 1 N N N N N NO BV/WART
158 22 2 2 1 1 1 1 1 2 3 1 4 1 1 22 3 2 1.2 1 1 2 2 1 2 1 1 1 1 1 1 1 6 1 N N N P N NO HIV
159 42 2 2 1 1 1 1 1 1 1 1 4 1 1 42 10y 1 2 1 1 2 2 1 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV
160 30 1 1 2 1 1 1 1 1 2 1 4 1 0 30 6m 1 2 1 12 2 1 1 1 1 1 2 2 2 1 1 1 1 n N N N N NO BV
161 37 2 3 1 1 1 3 1 1 2 1 4 2 1 37 5 1 1,3 1 1 2 2 1 1 1 1 1 1 1 1 1 6 1 N N N N N NO NV
162 52 1 2 1 1 1 3 1 2 1 1 4 1 1 52 1 1 1,2 1 1 2 1 3 1 1 1 1 1 2 4 2 5 1 N N N N N NO CAN
163 30 2 3 2 1 1 3 1 1 1 1 4 1 1 30 10 2 1 1 1 2 2 2 1 1 1 1 1 2 4 2 5 1 N N N N N NO CAN
164 28 1 3 2 1 1 1 1 2 2 1 4 1 1 30 14 1 3 1 1 2 1 1 6` 1 1 2 1 1 1 1 6 1 N N N N N NO NV
165 18 1 2 2 2 1 1 1 2 2 1 4 1 0 16 2y 1 1 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
166 28 2 4 3 1 1 1 1 1 1 1 4 1 1 28 1m 1 6 1 1 2 3 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
167 23 2 4 1 1 1 1 1 1 1 7 4 1 1 23 14 1 3 1 1 2 2 2 5 1 2 1 2 1 4 1 1,3 1 N N N N N NO BV/MPC
168 45 1 3 0 1 1 1 1 1 1 1 4 1 1 45 30 2 1 1 1 1 1 1 5 1 1 1 1 1 1 1 2 1 N N N N N NO others
169 21 1 3 2 1 1 1 1 1 1 1 4 1 1 21 10 1 1,3 1 1 2 1 1 5 1 2 1 2 1 4 1 1,3 1 N N N N N NO BV/MPC





















































































































































































































































































































































































































































































































































































































































































































DEMOGRAPHIC, BEHAVIOUR AND REPRODUCTIVE HISTORY INVESTIGATIONS
171 38 1 3 2 1 1 1 1 1 1 1 4 1 1 35 30 1 1,3 1 1 2 3 1 5 3 1 1 2 1 2 1 6 1 P P P N N NO TV





















































































































































































































































































































































































































































































































































































































































































































DEMOGRAPHIC, BEHAVIOUR AND REPRODUCTIVE HISTORY INVESTIGATIONS
173 40 1 3 3 1 1 1 1 1 1 1 4 1 1 38 2y 1 6 1 1 2 2 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO others
174 53 1 4 2 1 1 1 1 1 1 1 4 1 1 52 5m 2 1 1 1 1 3 1 5 1 1 1 1 1 1 1 2,3 1 N N N N N NO others
175 39 1 3 2 1 1 1 1 1 1 1 4 1 1 38 2y 1 3 1 1 1 2 2 5 1 1 1 1 1 1 1 6 1 N N N N N NO PID
176 30 2 4 3 1 1 1 1 1 1 7 4 1 1 30 3m 1 6 1 1 2 3 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
177 32 2 2 1 1 1 3 1 2 1 1 4 1 1 32 15 1 1,2 1 1 2 1 1 1 1 1 1 1 2 3 2 5 1 N N N N N NO CAN
178 55 1 4 3 1 1 1 1 1 1 1 4 1 1 55 7 1 6 1 1 2 2 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
179 39 1 3 1 1 1 1 1 3 1 7 4 1 1 39 .. 1 2,3 1 1 2 1 1 5 1 1 1 1 1 1 1 3 1 N N N N N NO others
180 28 2 4 2 1 1 3 1 1 1 2 4 1 1 27 15 1 2 1 1 1 3 2 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV
181 28 2 3 2 1 2 4 2 4 4 1 4 1 1 25 6m 2 6 1 1 2 3 2 4 1 5 1 2 2 2 1 1,3 1 P P P N N NO TV
182 24 1 4 3 1 1 1 1 1 1 7 4 1 1 19 3m 1 6 1 1 2 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
183 28 1 4 2 1 1 3 1 1 1 2 4 1 1 37 2m 1 3,2 1 1 2 3 2 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV
184 18 1 3 2 2 1 4 2 4 4 7 4 1 1 18 1w 1 2,3 1 1 2 1 1 6 1 1 1 1 1 1 1 1 1 N N N N N NO others
185 55 2 3 1 1 1 2 1 1 2 1 3 1 1 50 1m 1 2.5 1 1 2 2 2 5 1 1 1 1 1 1 1 1 3 N N N N N NO CA CERVIX
186 19 1 3 2 1 1 1 1 1 1 1 4 1 1 19 20 1 6 1 1 2 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO NV
187 22 1 4 3 1 1 1 1 1 1 1 4 1 1 21 2M 1 1 1 1 2 2 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO NV
188 44 1 4 0 1 1 1 1 1 1 1 4 1 1 44 15 1 6 1 1 2 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO NV
189 28 1 3 1 1 1 1 1 1 1 2 3 1 1 27 1y 2 4 1 1 2 2 1 1 1 1 1 1 1 1 1 4 1 N N N N N NO HERPES/CAN
190 37 1 4 2 1 1 3 1 1 1 2 4 1 1 37 15 1 1 1 1 1 3 2 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV
191 28 1 2 3 2 1 1 1 1 1 1 1 4 1 28 3m 10 1 1,3 1 1 2 1 1 5 1 2 1 2 1 4 1 1,3 N N N N N NO BV/MPC
192 29 1 4 2 2 2 4 2 4 4 2 4 1 1 16 365 2 6 1 1 2 3 2 4 1 5 1 2 2 2 1 1,3 1 P P P N N NO TV
193 28 1 3 2 1 1 1 1 1 1 7 4 1 1 28 2M 1 1 1 1 2 2 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
194 27 1 2 2 1 1 1 1 1 1 1 4 1 1 27 90 1 6 1 1 2 2 1 1 1 1 1 1 1 1 1 3,4 1 N N N N N NO MPC
195 24 1 3 2 1 2 3 2 4,2 1 1 4 1 1 24 2m 1 1 1 1 2 2 3 1 1 1 1 1 2 3 2 5,3 1 N N N N N NO CAN
196 25 1 3 2 1 1 3 1 1 1 7 4 1 1 25 3m 1 1 1 1 1 3 2 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV
197 27 1 3 0 1 1 1 1 1 1 7 4 1 1 26 1Y 1 3 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
198 36 2 3 2 1 1 1 1 1 1 1 4 1 1 33 3y 1 1,2 1 1 2 1 1 2 1 1 1 1 1 1 1 2 1 N N N N N NO others
199 55 1 4 1 1 2 1 2 1 1 6 4 1 1 55 1m 1 1,5 1 1 2 1 2 1 3 2 2 1 1 1 1 4,3 7 N N N N N NO CA CERVIX
200 55 1 3 2 1 1 3 1 1 1 7 4 1 1 55 14 1 3 1 1 1 3 2 3 2 1 1 2 2 4 1 1 1 N N N N N NO NV
201 31 1 4 1 1 1 1 1 1 1 7 4 1 1 31 1m 2 1,3 1 1 2 1 1 2 1 1 1 1 1 1 1 2 1 N N N N N NO LAP
202 37 1 3 2 1 1 1 1 1 1 7 4 1 1 33 3y 1 1,2 1 1 2 1 1 2 1 1 1 1 1 1 1 2 1 N N N N N NO others
203 50 1 4 2 1 1 3 1 1 1 2 4 1 1 55 3m 1 1 1 1 1 3 2 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV
204 27 1 2 2 2 1 1 1 2 2 1 4 1 0 26 1y 1 1 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
205 49 1 4 1 1 2 1 2 1 1 6 4 1 1 15 5y 1 1,5 1 1 2 1 2 1 3 2 2 1 1 1 1 3 7 N N N N N NO CA CERVIX
206 45 1 3 2 1 1 1 1 1 1 7 4 1 1 45 15 1 1,3 1 1 2 2 1 5 1 1 1 1 1 1 1 2 1 N N N N N NO LAP
207 36 1 4 2 1 1 1 1 2 2 1 4 1 0 35 1y 1 8 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO MC 
208 54 1 2 2 1 1 3 1 2 2 1 4 1 1 54 .. 2 1 1 2 2 1 1 1 1 1 1 1 2 3 2 4,5 6 N N N N N NO CAN
209 38 2 3 2 1 1 1 1 1 1 7 4 1 1 38 5m 1 1,3 1 1 2 2 1 5 1 1 1 1 1 1 1 2 1 N N N N N NO LAP
210 39 1 3 1 1 1 1 1 1 1 1 4 1 1 39 1OY 1 6 1 1 2 3 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
211 37 1 3 0 1 1 1 1 1 1 1 4 1 1 37 3M 1 1 1 1 2 3 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
212 26 1 3 1 1 1 1 1 1 1 1 4 1 1 26 20 1 6 1 1 2 3 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV





















































































































































































































































































































































































































































































































































































































































































































DEMOGRAPHIC, BEHAVIOUR AND REPRODUCTIVE HISTORY INVESTIGATIONS
214 42 1 3 1 1 1 1 1 1 1 6 3 1 1 42 3m 1 7 4 2 2 1 1 6 1 1 1 1 1 1 1 3 1 N N N N N NO HERPES





















































































































































































































































































































































































































































































































































































































































































































DEMOGRAPHIC, BEHAVIOUR AND REPRODUCTIVE HISTORY INVESTIGATIONS
216 35 1 4 1 1 1 2 1 3 1 1 4 1 1 35 25 2 1 1 1 2 2 2 6 3 1 1 1 1 1 1 6 1 P P P N N NO TV
217 26 1 4 2 1 1 1 1 1 1 1 3 1 1 26 5 1 2,3 1 2 2 2 1 1 1 1 1 1 1 1 1 3 1 N N N N N NO HERPES/CAN
218 28 1 2 2 2 1 1 1 2 2 1 4 1 0 26 1y 1 1 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
219 19 1 3 1 1 1 1 1 3 1 1 4 1 1 18 2y 1 2,1 1 1 1 1 1 3 2 1 1 2 2 3 2 1,4 1 N N N N N NO BV/CAN
220 35 1 4 0 1 1 1 1 3 1 7 4 1 1 35 2m 2 1 1 1 1 3 2 4 3 1 1 1 1 2 1 3,4 1 P P P N N YES TV/MPC
221 52 1 4 1 1 2 2 2 1 1 6 4 1 1 50 15 1 5 1 1 2 1 2 1 3 2 2 1 1 1 1 3 7 N N N N N NO CA CERVIX IIIA
222 30 2 3 2 1 1 1 1 1 1 1 4 1 1 30 20 1 1,2 1 1 2 3 1 6 1 1 1 1 1 1 1 3,4 1 N N N N N NO MPC
223 20 1 3 2 2 1 4 1 4 4 1 4 1 1 20 7 2 1, 1 1 2 1 1 2 1 5 1 1 1 1 1 6 1 N N N N N NO NV
224 18 1 4 2 1 1 3 1 1 1 2 4 1 1 37 2m 1 3,2 1 1 2 3 2 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV/CAN
225 35 1 3 1 1 1 2 1 3 4 1 2 1 1 35 7 1 3 1 1 2 2 1 5 1 1 1 1 1 1 1 1 1 N N N N N NO HEPB/NV
226 25 1 3 2 1 1 4 1 4 4 1 4 1 1 25 30 2 6 1 1 2 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO NV
227 27 1 3 2 1 1 4 1 4 4 1 4 1 1 26 7 2 6 1 1 2 1 1 6 1 1 1 1 1 1 1 3 1 N N N N N NO NV
228 54 2 3 2 1 1 4 1 4 4 1 4 1 1 54 20 2 6 1 1 2 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO NV
229 24 1 4 1 1 1 3 1 2 3 1 4 1 1 23 2m 1 1 1 1 2 2 2 6 1 1 1 1 2 1 1 2 1 P P P N N NO TV
230 45 1 4 2 1 1 4 1 4 4 1 4 1 1 45 30 2 6 1 1 2 1 1 2 1 1 1 1 1 1 1 3 1 N N N N N NO NV
231 32 1 3 2 1 1 4 1 4 4 1 4 1 1 32 15 2 6 1 1 2 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO NV
232 29 1 2 2 1 1 1 1 1 1 1 4 1 1 29 45 1 1,3 1 1 2 2 1 6 1 2 1 1 1 1 1 6 1 N N N N N NO MPC
233 20 2 3 2 2 1 4 1 4 4 1 4 1 1 20 5 2 6 1 1 2 1 1 2 1 5 1 1 1 1 1 6 1 N N N N N NO PHY
234 28 1 4 1 1 1 3 1 1 1 2 4 1 1 28 30 1 3 1 1 2 3 2 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV
235 45 2 2 0 1 1 1 1 1 1 1 4 1 1 45 3y 2 3 1 1 2 1 1 2 1 2 1 1 1 3 1 3,4 1 N N N N N NO VVC/MPC
236 26 1 4 1 1 1 3 1 1 1 2 4 1 1 37 2m 1 3,2 1 1 2 3 2 3 2 2 1 2 2 4 1 1 1 N N N N N NO MC/BV
237 45 1 3 2 1 1 1 1 1 1 1 4 1 1 42 2y 1 1 1 1 2 1 1 4 1 1 1 1 1 1 1 3 1 N N N N N NO others
238 50 2 4 2 1 2 1 1 1 1 1 4 1 1 50 9o 1 1,3 1 1 2 2 1 5 1 2 1 1 1 1 1 4 1 N N N N N NO MPC
239 42 1 2 3 1 2 1 1 1 1 1 4 1 1 42 60 2 1,2 1 1 2 3 1 5 1 2 1 1 1 1 1 4 1 N N N N N NO MPC
240 28 1 3 2 1 1 1 1 1 1 1 4 1 1 27 1yr 2 6 1 1 2 1 2 2 1 1 1 1 1 1 1 6 1 N N N N N NO NV
241 20 1 4 1 1 2 2 1 2 6 1 4 1 1 18 2y 2 3,1,5 1 1 2 3 1 3 2 1 1 2 2 4 1 3,4 1 N N N N N NO HIV/BV
242 35 1 2 2 1 1 1 1 1 1 1 4 1 1 34 1y 2 3 1 1 2 2 1 5 1 2 1 1 1 1 1 4 1 N N N N N NO MPC
243 45 1 3 1 1 2 1 1 1 1 1 4 1 1 45 10 1 6 1 1 2 1 2 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
244 40 1 3 1 1 1 1 1 1 1 1 4 1 1 35 5yr 2 3 1 1 2 2 1 5 1 3 1 1 1 1 1 3 1 N N N N N NO CERVICAL GROWTH
245 20 1 4 0 1 1 1 1 1 1 1 4 1 1 20 4m 1 6 1 1 2 1 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
246 32 1 2 2 2 2 2 1 2 2 1 4 1 1 32 6m 2 2,3 1 1 2 2 2 6 3 1 1 2 2 1 1 4 1 P P N N N YES TV/MPC
247 42 1 4 0 1 1 1 1 1 1 1 4 1 1 42 9m 1 1,3 1 1 2 2 1 5 1 1 1 1 1 1 1 5 1 N N N N N NO MPC/LAP
248 30 1 3 1 1 1 1 1 1 1 1 4 1 1 28 2y 1 1,2 1 1 2 1 1 5 1 1 1 1 2 3 2 3 1 N N N N N NO HIV/CAN
249 30 1 2 2 1 1 1 1 1 1 1 4 1 1 30 1y 1 6 1 1 2 2 1 6 1 1 1 1 1 1 1 3 1 N N N N N NO NV
































































































































































































































































































































































































































































































































































































































































































































1 42 1 2 2 1 1 1 1 2 2 1 4 1 1 0 0 0 6 1 1 2 1 1 5 1 2 1 1 1 1 1 6 1 N N N N N NO NV
2 28 1 3 2 1 1 1 1 2 2 1 4 1 1 0 0 0 6 2 1 2 3 1 1 1 1 1 1 1 1 1 5 1 N N N N N NO CAN
3 20 1 4 1 1 1 1 1 3 1 7 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
4 28 1 4 0 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
5 40 1 2 2 1 1 3 1 1 1 7 4 1 1 0 0 0 6 1 1 2 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
6 46 1 3 1 1 1 1 1 1 1 1 4 1 1 0 0 0 6 1 1 2 2 1 3 1 1 1 2 2 4 1 1 1 N N N N N NO BV
7 32 1 3 1 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 2 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV
8 22 1 2 2 1 1 1 1 3 4 1 4 1 1 0 0 0 6 1 1 2 1 1 5 1 1 1 1 1 1 1 5 1 N N N N N NO NV
9 30 1 2 1 1 1 1 1 1 2 7 4 1 1 0 0 0 6 1 1 2 1 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
10 50 1 3 2 1 1 1 1 1 2 1 4 1 1 0 0 0 6 1 1 2 1 1 6 1 5 1 1 1 3 2 5 1 N N N N N NO CAN
11 37 1 2 1 2 1 1 1 1 4 7 5 1 1 0 0 0 6 1 1 2 1 1 5 1 1 1 1 1 1 1 6 1 N N N P N NO HIV+
12 35 1 3 2 1 1 3 1 1 2 1 4 1 1 0 0 0 6 1 1 2 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
13 38 1 3 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 1 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
14 22 1 4 1 1 1 3 1 3 2 1 4 1 1 0 0 0 6 1 1 2 1 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
15 30 2 4 1 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO NV
16 45 1 4 1 1 1 1 1 1 2 1 4 1 1 0 0 0 6 1 1 2 1 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
17 52 1 4 1 3 1 3 1 1 1 7 4 1 1 0 0 0 6 1 1 1 1 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
18 29 1 2 2 1 1 1 1 3 4 7 1 4 1 0 0 0 6 1 1 1 1 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
19 45 1 4 2 1 1 1 1 1 1 1 4 1 1 0 0 0 6 1 1 1 2 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO NV
20 50 1 3 1 1 1 3 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 1 1 1 1 1 2 3 2 5 1 N N N N N NO CAN
21 32 2 3 1 1 1 1 1 2 1 7 4 1 1 0 0 0 6 1 1 1 2 1 1 1 1 1 1 1 1 1 6 1 N N N N N NO NV
22 23 1 4 2 1 1 1 1 2 2 7 4 1 1 0 0 0 6 1 1 2 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO NV
23 42 1 4 2 1 1 1 1 1 1 1 4 1 1 0 0 0 6 1 1 2 1 1 6 1 1 1 1 1 3 1 6 1 N N N N N NO NV
24 45 1 2 1 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 1 1 1 1 1 1 1 1 1 1 6 1 N N N N N NO NV
25 47 1 2 1 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 1 1 6 4 1 1 1 1 1 1 6 1 N N N N N NO NV
26 40 1 3 1 1 1 1 1 1 1 2 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 2 2 4 1 1 1 N N N N N NO BV
27 39 1 4 0 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 2 1 5 4 1 1 1 1 1 1 6 1 N N N N N NO NV
28 33 1 4 2 1 2 1 1 1 1 2 4 1 1 0 0 0 6 2 1 2 3 2 6 3 1 1 2 1 1 1 3,4 1 N N N N N NO MPC
ASYMPTOMATIC PATIENTS
































































































































































































































































































































































































































































































































































































































































































































29 24 1 3 1 1 1 1 1 3 2 7 4 1 1 0 0 0 6 1 1 2 2 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
30 26 1 2 1 1 1 1 1 1 1 1 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 2 1 1 1 2 1 N N N N N NO others
31 35 1 3 2 1 1 1 1 1 2 1 4 1 1 0 0 0 6 1 1 1 1 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
32 48 1 4 0 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
33 29 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
34 32 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
35 45 1 3 2 1 1 1 1 2 2 1 4 1 1 0 0 0 6 2 1 2 3 1 1 1 1 1 1 1 3 1 5 1 N N N N N NO CAN
36 32 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
37 29 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
38 45 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO HIV+
39 53 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
40 46 1 4 2 1 2 1 1 1 1 2 4 1 1 0 0 0 6 2 1 2 3 2 6 3 1 1 2 1 1 1 3,4 1 N N N N N NO MPC
41 40 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
42 38 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO others
43 23 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
44 32 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
45 32 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
46 27 1 3 1 1 1 1 1 1 1 7 4 1 1 0 0 0 3 1 1 2 2 2 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV
47 28 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
48 42 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
49 35 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO others
50 18 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
51 45 1 3 1 1 1 1 1 3 1 7 4 1 1 0 0 0 6 1 1 1 2 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
52 50 1 4 0 3 2 4 2 1 1 7 4 1 2 0 0 0 6 1 1 2 1 1 6 1 1 1 2 2 1 1 4 2 p p p n n NO TV/BV
53 32 1 4 2 1 2 1 1 1 1 2 4 1 1 0 0 0 6 2 1 2 3 2 6 3 1 1 2 1 1 1 3,4 1 N N N N N NO BV/MPC
54 35 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
55 36 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
56 24 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
57 55 1 3 2 1 1 1 1 2 2 1 4 1 1 0 0 0 6 2 1 2 3 1 1 1 1 1 1 1 1 1 5 1 N N N N N NO CAN
































































































































































































































































































































































































































































































































































































































































































































59 39 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
60 26 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
61 27 1 4 2 1 2 1 1 1 1 2 4 1 1 0 0 0 6 2 1 2 3 2 5 3 1 1 2 1 1 1 3,4 1 N N N N N NO MPC
62 37 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
63 30 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 3 1 1 1 1 1 1 1 6 1 N N N N N NO NV/CONTACT SY2
64 37 1 4 2 1 2 1 1 1 1 2 4 1 1 0 0 0 6 2 1 2 3 2 6 3 1 1 2 1 1 1 3,4 1 N N N N N NO MPC
65 45 1 3 2 1 1 3 1 1 1 1 4 1 1 0 0 0 6 1 1 2 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
66 28 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
67 52 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
68 38 1 2 2 1 1 3 2 3 1 1 4 1 1 0 0 0 6 1 1 2 2 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
69 33 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO others
70 45 1 4 2 1 2 1 1 1 1 2 4 1 1 0 0 0 6 2 1 2 3 2 3 3 1 1 2 1 1 1 3,4 1 N N N N N NO MPC
71 26 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
72 25 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
73 50 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
74 25 1 3 2 1 1 1 1 2 2 1 4 1 1 0 0 0 6 2 1 2 3 1 1 1 1 1 1 1 3 1 5 1 N N N N N NO CAN
75 40 1 3 2 1 1 1 1 2 2 1 4 1 1 0 0 0 6 2 1 2 3 1 5 1 1 1 1 1 1 1 5 1 N N N N N NO CAN
76 38 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
77 42 1 4 2 1 2 1 1 1 1 2 4 1 1 0 0 0 6 2 1 2 3 2 6 3 1 1 2 1 1 1 3,4 1 N N N N N NO MPC
78 25 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
79 36 1 3 2 1 1 1 1 2 2 7 4 1 1 0 0 0 6 2 1 2 3 1 1 1 1 1 1 1 1 1 5 1 N N N N N NO CAN
80 35 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
81 32 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO others
82 46 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO 0thers
83 45 1 3 0 1 1 3 2 3 1 1 4 1 1 0 0 0 6 1 1 2 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
84 38 2 3 2 1 1 1 1 2 2 1 4 1 1 0 0 0 6 2 1 2 3 1 1 1 1 1 1 1 1 1 5 1 N N N N N NO CAN
85 24 1 4 2 1 1 1 2 2 1 1 4 1 1 0 0 0 6 1 1 2 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
86 45 1 2 0 1 1 3 2 1 1 1 4 1 1 0 0 0 6 1 1 1 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
87 20 1 3 2 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 5 1 N N N N N NO PHY
































































































































































































































































































































































































































































































































































































































































































































89 25 1 4 0 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
90 45 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
91 19 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
92 48 1 3 1 1 1 1 1 1 1 7 4 1 1 0 0 0 3 1 1 2 2 2 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV
93 22 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
94 22 1 3 2 1 1 1 2 2 1 1 4 1 1 0 0 0 6 1 1 2 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO NV
95 18 1 3 2 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 5 1 N N N N N NO PHY
96 28 1 4 1 1 1 3 2 1 1 1 4 1 1 0 0 0 6 1 1 2 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO NV
97 40 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
98 33 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
99 40 1 3 2 1 1 1 1 2 2 1 4 1 1 0 0 0 6 2 1 2 3 1 1 1 1 1 1 1 3 1 5 1 N N N N N NO CAN
100 24 1 3 1 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 2 1 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
101 18 1 4 2 1 1 1 2 4 4 7 4 1 1 0 0 0 6 1 1 1 1 1 5 4 1 1 1 1 1 1 2 1 N N N N N NO NV
102 30 1 4 1 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 2 1 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
103 42 1 3 2 1 1 1 1 2 2 1 4 1 1 0 0 0 6 2 1 2 3 1 1 1 1 1 1 1 1 1 5 1 N N N N N NO CAN
104 30 1 3 1 2 2 4 1 1 1 6 3 1 0 0 0 0 6 1 1 2 2 1 6 3 2 2 2 2 2 1 3,4 2 P P P p n YES TV/MPC/HIV
105 28 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 6 1 1 2 3 2 4 3 1 1 2 1 1 2 4 1 p p p n n NO TV
106 40 1 3 1 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 2 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV
107 23 1 3 2 1 1 1 2 2 1 1 4 1 1 0 0 0 6 1 1 2 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
108 36 1 4 2 1 2 1 1 1 1 2 4 1 1 0 0 0 6 2 1 2 3 2 6 3 1 1 2 1 1 1 3,4 1 N N N N N NO MPC
109 24 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
110 23 1 4 0 1 1 1 2 2 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
111 48 1 4 0 1 1 1 2 1 1 7 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
112 38 1 3 2 1 1 1 1 2 2 1 4 1 1 0 0 0 6 2 1 2 3 1 1 1 1 1 1 1 3 1 5 1 N N N N N NO CAN
113 35 1 4 0 1 1 1 2 1 1 7 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
114 31 1 4 0 1 1 1 2 1 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
115 47 1 3 2 1 1 1 1 1 2 7 4 1 1 0 0 0 6 1 1 2 1 2 5 1 2 1 1 1 1 1 3,4 1 N N N N N NO MPC
116 27 1 3 2 1 1 1 1 3 2 1 4 1 1 0 0 0 6 1 1 2 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO PHY
117 31 1 3 2 1 1 1 1 3 1 3 4 1 1 0 0 0 6 1 1 2 2 2 3 1 1 1 2 2 1 1 1 1 N N N N N NO BV
































































































































































































































































































































































































































































































































































































































































































































119 30 2 3 0 1 1 1 1 2 2 7 4 1 1 0 0 0 6 1 1 2 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO NV
120 25 1 4 2 1 1 3 1 2 2 6 4 1 1 0 0 0 6 1 1 1 1 1 2 1 1 1 1 1 1 1 6 1 N N N N N NO NV
121 27 1 3 1 1 1 2 1 3 1 1 4 1 1 0 0 0 6 1 1 2 2 1 1 1 1 1 1 2 3 2 5 1 N N N N N NO CAN
122 24 1 4 1 2 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 6 1 1 1 1 1 1 1 5 1 N N N N N NO NV
123 35 1 4 0 1 1 1 1 1 2 6 4 1 1 0 0 0 6 1 1 2 2 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
124 19 1 4 2 2 1 4 1 4 4 6 4 1 1 0 0 0 6 1 1 2 2 1 3 1 1 1 1 2 1 1 1,4 1 N N N N N NO BV
125 26 1 3 1 1 1 1 1 2 2 6 4 1 1 0 0 0 6 1 1 2 1 1 6 1 1 1 2 1 4 12 6 1 N N N N N NO NV
126 45 1 3 2 1 1 2 1 1 1 3 4 1 1 0 0 0 6 3 1 2 1 1 1 1 1 1 1 1 3 1 6 1 N N N N N NO CAN
127 40 1 3 1 1 1 3 1 1 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
128 31 1 3 0 1 1 1 1 1 2 6 4 1 1 0 0 0 6 3 1 2 1 1 6 1 1 1 1 2 3 2 6 1 N N N N N NO NV
129 21 1 4 1 1 1 3 1 2 1 6 4 1 1 0 0 0 6 1 1 2 1 1 3 1 1 1 2 2 4 1 1 1 N N N N N NO BV
130 38 1 4 1 1 1 1 1 2 2 1 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 1 1 N N N N N NO NV
131 36 1 4 0 1 1 1 2 1 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
132 33 1 4 1 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
133 40 1 3 2 1 1 1 2 1 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
134 55 1 3 2 1 1 1 1 2 2 1 4 1 1 0 0 0 6 2 1 2 3 1 1 1 1 1 1 1 3 1 5 1 N N N N N NO CAN
135 25 1 3 0 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
136 25 1 4 1 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
137 35 1 3 0 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 2 1 N N N N N NO others
138 26 1 4 2 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
139 43 1 2 0 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
140 36 1 4 2 1 2 1 1 1 1 2 4 1 1 0 0 0 6 2 1 2 3 2 6 3 1 1 2 1 1 1 3,4 1 N N N N N NO MPC
141 29 1 4 0 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
142 35 1 3 1 1 1 1 1 1 1 1 4 1 2 0 0 0 6 1 1 2 2 1 6 1 1 2 2 2 1 2 4 1 P P P n n NO TV
143 27 1 4 2 1 2 1 1 1 1 2 4 1 1 0 0 0 6 2 1 2 3 2 6 3 1 1 2 1 1 1 3,4 1 N N N N N NO MPC
144 50 1 4 0 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
145 40 1 2 0 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
146 36 1 4 2 1 2 1 1 1 1 2 4 1 1 0 0 0 6 2 1 2 3 2 6 3 1 1 2 1 1 1 3,4 1 N N N N N NO MPC
147 20 2 4 0 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
































































































































































































































































































































































































































































































































































































































































































































149 50 1 4 2 1 2 1 1 1 1 2 4 1 1 0 0 0 6 2 1 2 3 2 6 3 1 1 2 1 1 1 3,4 1 N N N N N NO MPC
150 28 1 3 1 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
151 32 1 4 0 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
152 32 1 3 1 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
153 30 1 2 1 1 1 1 1 1 2 1 4 1 1 0 0 0 6 1 1 2 2 1 3 2 1 1 2 2 4 1 1 1 n n n n n NO BV
154 28 1 4 2 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
155 33 1 3 2 1 1 1 1 2 2 1 4 1 1 0 0 0 6 2 1 2 3 1 1 1 1 1 1 1 3 1 6 1 N N N N N NO CAN
156 26 1 3 1 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
157 28 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
158 36 1 2 1 1 1 1 1 1 2 1 4 1 1 0 0 0 6 1 1 2 2 1 3 2 1 1 2 2 4 1 1 1 n n n n n NO BV
159 42 1 3 0 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
160 45 1 3 2 1 1 1 1 2 2 1 4 1 1 0 0 0 6 2 1 2 3 1 1 1 1 1 1 1 1 1 3.5 1 N N N N N NO CAN
161 39 1 3 2 1 1 1 1 2 2 1 4 1 1 0 0 0 6 2 1 2 3 1 1 1 1 1 1 1 3 1 5 1 N N N N N NO CAN
162 40 1 4 0 1 2 1 1 1 1 2 4 1 1 0 0 0 6 2 1 2 3 2 6 3 1 1 2 1 1 1 3,4 1 N N N N N NO MPC
163 28 1 3 1 1 1 1 1 1 2 1 4 1 1 0 0 0 6 1 1 2 2 3 4 3 1 1 2 2 2 1 1,3 1 P P P N N YES TV/BV
164 32 1 4 0 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
165 48 1 3 2 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
166 30 1 4 2 1 2 1 1 1 1 2 4 1 1 0 0 0 6 2 1 2 3 2 6 3 1 1 2 1 1 1 3,4 1 N N N N N NO MPC
167 35 2 3 1 1 1 1 1 2 2 1 4 1 1 0 0 0 6 2 1 2 3 1 1 1 1 1 1 1 3 1 5 1 N N N N N NO CAN
168 54 1 3 1 1 1 1 1 2 2 1 4 1 1 0 0 0 6 2 1 2 3 1 1 1 1 1 1 1 3 1 5 1 N N N N N NO CAN
169 21 1 4 0 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
170 50 1 4 1 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
171 50 1 4 0 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
172 30 1 3 2 1 1 1 1 2 2 1 4 1 1 0 0 0 6 2 1 2 3 1 1 1 1 1 1 1 3 1 5 1 N N N N N NO CAN
173 28 1 4 2 1 2 1 1 1 1 2 4 1 1 0 0 0 6 2 1 2 3 2 6 3 1 1 2 1 1 1 3,4 1 N N N N N NO HIV
174 50 1 3 2 1 1 1 1 2 2 1 4 1 1 0 0 0 6 2 1 2 3 1 1 1 1 1 1 1 1 1 5 1 N N N N N NO CAN
175 40 1 4 2 1 2 1 1 1 1 2 4 1 1 0 0 0 6 2 1 2 3 2 6 3 1 1 2 1 1 1 3,4 1 N N N N N NO MPC
176 48 1 4 1 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
177 45 1 4 0 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
































































































































































































































































































































































































































































































































































































































































































































179 30 1 4 1 1 2 3 1 1 1 2 4 1 0 0 0 0 6 1 1 2 2 1 5 1 1 1 1 1 1 1 6 1 P P P N N NO TV
180 23 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
181 55 1 3 2 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 5 1 N N N N N NO PHY
182 19 1 3 1 1 1 1 1 1 2 1 4 1 1 0 0 0 6 1 1 2 1 1 2 1 1 1 2 2 2 1 1,4 1 P P P N N YES TV/BV
183 22 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
184 41 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
185 41 1 4 1 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
186 36 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
187 30 1 3 1 2 2 3 1 1 2 1 4 1 1 0 0 0 6 1 1 2 3 2 5 1 1 1 2 2 2 1 4 1 N P P P N YES TV/BV
188 38 2 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
189 55 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
190 28 1 3 2 1 1 1 1 2 2 1 4 1 1 0 0 0 6 2 1 2 3 1 1 1 1 1 1 1 1 1 5 1 N N N N N NO CAN
191 46 1 2 1 1 1 1 1 1 2 1 4 1 1 0 0 0 6 1 1 2 2 1 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV
192 36 1 4 2 1 2 1 1 1 1 2 4 1 1 0 0 0 6 2 1 2 3 2 6 3 1 1 2 1 1 1 3,4 1 N N N N N NO MPC
193 33 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
194 34 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
195 20 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO HIV
196 28 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
197 32 1 2 1 1 1 1 1 1 2 1 4 1 1 0 0 0 6 1 1 2 2 1 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV
198 22 1 3 2 1 1 1 1 2 2 1 4 1 1 0 0 0 6 2 1 2 3 1 1 1 1 1 1 1 3 1 5 1 N N N N N NO CAN
199 18 1 4 0 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
200 28 1 4 0 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
201 27 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO HIV
202 45 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
203 25 2 2 1 1 1 1 1 1 2 1 4 1 1 0 0 0 6 1 1 2 2 1 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV
204 25 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
205 24 1 4 2 1 2 1 1 1 1 2 4 1 1 0 0 0 6 2 1 2 3 2 6 3 1 1 2 1 1 1 3,4 1 N N N N N NO MPC
206 27 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
207 28 1 3 0 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 2 3 2 1 1 2 2 4 1 1 1 N N N N N NO CAN/BV
































































































































































































































































































































































































































































































































































































































































































































209 36 1 4 2 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
210 55 1 4 1 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
211 56 1 4 2 1 2 1 1 1 1 2 4 1 1 0 0 0 6 2 1 2 3 2 6 3 1 1 2 1 1 1 3,4 1 N N N N N NO MPC
212 18 1 4 1 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
213 38 1 4 1 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
214 19 1 4 0 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
215 36 1 4 0 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
216 27 2 4 1 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
217 35 1 4 0 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
218 37 2 3 2 1 1 1 1 2 2 1 4 1 1 0 0 0 6 2 1 2 3 1 1 1 1 1 1 1 3 1 5 1 N N N N N NO CAN
219 39 1 4 0 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
220 26 1 4 2 1 2 1 1 1 1 2 4 1 1 0 0 0 6 2 1 2 3 2 6 3 1 1 2 1 1 1 3,4 1 N N N N N NO MPC
221 26 1 4 0 1 1 1 2 3 2 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
222 25 1 2 1 1 1 1 1 1 2 1 4 1 1 0 0 0 6 1 1 2 2 1 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV
223 27 1 2 1 1 1 1 1 1 2 1 4 1 1 0 0 0 6 1 1 2 2 1 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV
224 29 1 4 2 1 2 1 1 1 1 2 4 1 1 0 0 0 6 2 1 2 3 2 6 3 1 1 2 1 1 1 3,4 1 N N N N N NO MPC
225 37 1 3 2 1 1 1 1 2 1 7 4 1 1 0 0 0 6 2 1 2 3 1 1 1 1 1 1 1 3 1 5 1 N N N N N NO CAN
226 35 1 3 2 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 5 1 N N N N N NO PHY
227 45 1 4 0 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
228 30 1 4 2 1 2 1 1 1 1 2 4 1 1 0 0 0 6 2 1 2 3 2 6 3 1 1 2 1 1 1 3,4 1 N N N N N NO MPC
229 20 1 4 0 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
230 24 1 4 0 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
231 24 1 3 2 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 5 1 N N N N N NO others
232 40 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
233 35 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
234 48 1 3 2 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 5 1 N N N N N NO CAN
235 22 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
236 35 1 2 1 1 1 1 1 1 2 1 4 1 1 0 0 0 6 1 1 2 2 1 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV
237 40 1 4 2 1 1 1 1 1 1 7 4 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 1 1 1 1 6 1 N N N N N NO NV
































































































































































































































































































































































































































































































































































































































































































































239 23 1 4 2 1 2 1 1 1 1 2 4 1 1 0 0 0 6 2 1 2 3 2 6 3 1 1 2 1 1 1 3,4 1 N N N N N NO PHY
240 35 1 3 2 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 5 1 1 1 1 1 1 1 5 1 N N N N N NO NV
241 34 1 3 1 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 2 2 1 5 1 1 1 1 1 1 1 6 1 N N N N N NO NV
242 24 1 2 1 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 1 1 1 6 1 1 1 1 1 1 1 5 1 N N N N N NO NV
243 36 1 3 1 1 1 1 1 1 1 7 4 1 1 0 0 0 3 1 1 2 2 2 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV
244 36 2 3 1 1 1 1 1 1 1 7 4 1 1 0 0 0 3 1 1 2 2 2 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV/CAN
245 38 1 4 2 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 2 2 1 5 4 1 1 1 1 1 1 6 1 N N N N N NO NV
246 40 1 4 2 1 2 1 1 1 1 2 4 1 1 0 0 0 6 2 1 2 3 2 6 3 1 1 2 1 1 1 3,4 1 N N N N N NO MPC
247 35 1 4 2 1 2 1 1 1 1 2 4 1 1 0 0 0 6 2 1 2 3 2 6 3 1 1 2 1 1 1 3,4 1 N N N N N NO MPC
248 23 1 4 2 1 1 1 2 3 1 1 4 1 1 0 0 0 6 1 1 2 1 1 6 4 1 1 1 1 1 1 6 1 N N N N N NO NV
249 45 1 2 1 1 1 1 1 1 2 1 4 1 1 0 0 0 6 1 1 2 2 1 3 2 1 1 2 2 4 1 1 1 N N N N N NO BV
250 35 2 3 1 1 1 3 1 1 2 1 3 1 1 0 0 0 6 1 1 2 2 1 6 1 1 1 2 1 2 1 6 1 P P P P N YES TV/BV
MASTER CHART CODING 
A.  Serial number 
 




D. Socioeconomic status:              1 Upper middle. 
                                           2  Lower middle.  
                                           3 Upper lower. 
                                           4. Lower lower 
E. Education status:        1. Nil                                 
                        2. 6th- 10th3. 
                                                
  3. Graduate 
                                  4 Professional 
F. Marital status :     1. Married  
                                       2.Single women 
   3. Widow 
G. Pre/extramarital status:    1. Absent  2.present 
H. Husband with extra marital contact:  1 Absent 
2 Present 
3 Unknown  
4 Notapplicable 
I. Involvement in prostitution   1.No  2.Yes 
J. Contraception:- 
        1. Sterilization  2.Barrier   3.IUCD   4. Nil  
K. Obestretic history :  
 1. Normal delivery   2.LSCS    3.Abortion 4.nil 
L. Symptoms in partner: 
1 Unknown  
2 .Urethritis 
3 .Dysuria  
4 .Balanitis 





M. Past history  PID /infertility/PVD : 
1.PID 
 2.infertility  
3.veneral disease  
4.absent 
N. Treatment received in past 3 weeks:   1.No   2.Yes 
O. Substance abuse:      1.No   2.Yes 
P. Age at onset:- 
Q. Duration of vaginal discharge:- 
R. Relation to menstruation:    1. No  2.yes 
S. Other symptoms  
1. Vulval itching               6.None 
2. Dysuria     7.Ulcer 
3. Lower abdominal pain   8. Growth/swelling 
4.Dyspareunia 
5. Post coital bleeding  
[P,Q ,R,S is not applicable in  asymptomatic group] 
T. Vulvar examination   1. Normal   2. Erythema  3.Growth  
4.Ulcer 
U. Genital ulcer    1. Absent  2.  Present 
V. Vaginal Discharge:   1. Absent   2. Present 
W. Discharge amount:   1. Scanty  2. Moderate  3.Profuse 
X. Discharge odour  
 1. Odourless  2.Foul smelling  3 Fishy 
Y. Discharge consistency 
1. Curdy   2. Flocculent 3. Thick homogeneous  4 .Frothy 5 Watery   
6. Mucoid 
Z. Discharge color: 
1.White   2. Greyish 3.Purulent 4. Serosanguinous 
AA. Cervical Examination: 
                1. Normal 2.Erosion 3.Growth 4.Erythema 5. Not examined  
AB. Adenexal tenderness:-  1.No   2. Yes 
AC.Ph range:      1. < 4.5        2. >4.5 
AD. Whiff test:   1 negative  2 positive 
AE.Wet mount  :  1 negative   2 TV  3 yeast cells 4clue cells 
AF. KOH mount:   1 negative   2 budding yeast cells  
AG. Grams stain: 
1 clue cells  
2 Gram positive rods  
3 Epithelial cells  
4 Pus cells 
5 Yeast cells 
6 TV 
AH.Pap smear: 
1 Normal      2.TV .   3.HGSIL   4.SCC      5.AGNOS      6. ASCUS 
7.Adenocarcinoma 
     AI.  Trichomonas culture : 
 AI.  2nd & 3rd day    present   absent 
AJ.     5th day  present absent 
AK.   7th  day present absent 
AL.  HIV     1. NonReactive 2 Reactive 
AM.  VDRL  1. Negative 2. positive 
AN.  Coexistent STI:  1.No 2.Yes 
AO. Final diagnosis 
TV: Trichomonas vaginalis 
BV: Bacterial vaginalis 
MPC: Mucopurulent Cervicitis 
CAN: Candidiasis 
HERPES: Herpes Genitalis 
HIV: Human Immunodeficiency Virus 
BC: Bartholin’s Cyst 
LC: Lymphangioma Circumcriptum 








Comparative study of Trichomonas vaginalis infection in symptomatic and
asymptomatic female patients attending STD outpatient department
diagnosed by wet mount and culture method”
Assignment
title Medical





First 100 words of your submission
INTRODUCTION Trichomoniasis also known as trich, is caused by pathogenic protozoan
Trichomonas vaginalis (T.vaginalis), which is the most common non- viral sexually transmitted
infection (STI). Trichomoniasis accounts for more than half of all curable sexually transmitted
infections worldwide 1 . It causes approximately 180 million infections worldwide annually. Many
infected persons remain asymptomatic, when symptomatic, it presents with vaginitis, cervicitis, PID
and infertility in women and non-gonococcal urethritis in men. Women infected during pregnancy are
predisposed to adverse pregnancy outcomes like premature rupture of membrane, premature labour
and low birth weight infants. 2...
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